[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"LW Scientific, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":197},{"warningLetters":4,"total":196},[5,31,52,73,95,115,139,159,178],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1024,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-03T05:00:00Z\">03\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvivid-scientific-llc-699226-03032025\">Vivid-Scientific LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Lisa L. Currin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Vivid-Scientific LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>203 East Main Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jamestown\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27282\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@vividscientific.com\"> support@vividscientific.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vividscientificllc@gmail.com\"> vividscientificllc@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 3, 2025\u003C\u002Fp>\u003Cp>RE: 699226\u003C\u002Fp>\u003Cp>Dear Lisa Currin:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.vividscientific.com\u002F in January 2025 and has observed that your website offers various injectable lipolytic products, such as “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster,” for sale in the United States. As described below, your “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>On your “LemonBottle Ampoule Solution” webpage https:\u002F\u002Fwww.vividscientific.com\u002Flemonbottle-fat-dissolver-5-vials--no-kit.html:\u003C\u002Fp>\u003Cp>􀁸 “FAT DISSOLVER”\u003Cbr>􀁸 “The plant and vitamin based formulation dissolves localized cellulite and fat, tightens skin, and improves overall health.”\u003Cbr>􀁸 “Dissolve Fat &amp; Cellulite - immediately breaks down fat cells (including cellulite) and speeds up metabolism.”\u003Cbr>􀁸 “Anti Aging – Centella Asiatica extract stimulates collagen, has anti-inflammatory properties, and is an excellent antioxidant”\u003Cbr>􀁸 “Increased Metabolism &amp; Energy – Riboflavin (Vit B2) specializes in extracting energy from food while burning fat + functions as an antioxidant supporting the immune system, healthy skin, and hair.”\u003C\u002Fp>\u003Cp>On your “Lipo Lab PPC Solution” webpage https:\u002F\u002Fwww.vividscientific.com\u002FLipoLab-Max-NO-KIT_p_57.html:\u003C\u002Fp>\u003Cp>􀁸 “Permanently dissolve fat and cellulite while increasing collagen and elastin with Lipo Lab's proprietary lipolysis formula.”\u003Cbr>􀁸 “Treatment with Lipo Lab produces rapid fat loss and prevents wrinkles and sagging as the fat layer shrinks.”\u003Cbr>􀁸 “Dissolve stubborn fat and cellulite”\u003Cbr>􀁸 “Increase metabolism”\u003Cbr>􀁸 “Boost energy levels”\u003Cbr>􀁸 “[S]odium deoxycholate breaks down the membranes of fat cells allowing phosphatidylcholine (PPC) to enter and dissolve fatty acid molecules.”\u003Cbr>􀁸 “L-carnitine, the third active ingredient, acts as a carrier molecule, facilitating the transport of fatty acids into the mitochondria, where they are converted into energy.”\u003Cbr>􀁸 “The active ingredients are naturally occurring molecules that dissolve fat and cellulite permanently. Treated fat cells can no longer store fat.”\u003C\u002Fp>\u003Cp>On your “Neobella Extreme” webpage https:\u002F\u002Fwww.vividscientific.com\u002FNEOBELLAEXTREME-5-VIALS-NO-KIT_p_64.html:\u003C\u002Fp>\u003Cp>􀁸 “Target stubborn cellulite and fatty problem areas. . . . Results are permanent! Once the fat cells are dissolved, they are gone for good.”\u003Cbr>􀁸 “PERMANENT FAT REMOVAL + SKIN TIGHTENING IN ONE SYSTEM.”\u003Cbr>􀁸 “Fat dissolving injections provide a non-surgical, gentle method of sculpting the body gradually and artistically.”\u003Cbr>􀁸 “The main active ingredient is deoxycholic acid, a naturally occurring molecule that breaks down and destroys fat.”\u003C\u002Fp>\u003Cp>On your “Deoxycholic Acid Booster” webpage https:\u002F\u002Fwww.vividscientific.com\u002Fdeoxycholic-acid-fat-dissolving-booster-10ml.html:\u003C\u002Fp>\u003Cp>􀁸 “DEOXYCHOLIC ACID FAT DISSOLVING BOOSTER contains the same deoxycholic acid formulation as KYBELLA.”\u003Cbr>􀁸 “The BOOSTER can be added to lipolysis serums (Neobella, LipoLab, etc.) to increase efficacy and accelerate results.”\u003C\u002Fp>\u003Cp>Your “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “699226” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLisa L. Currin\n\nVivid-Scientific LLC\n\n203 East Main Street\n\nJamestown, NC 27282\n\nUnited States\n\nsupport@vividscientific.com\n\nvividscientificllc@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 3, 2025\nRE: 699226\nDear Lisa Currin:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.vividscientific.com\u002F in January 2025 and has observed that your website offers various injectable lipolytic products, such as “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster,” for sale in the United States. As described below, your “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nYour products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\nOn your “LemonBottle Ampoule Solution” webpage https:\u002F\u002Fwww.vividscientific.com\u002Flemonbottle-fat-dissolver-5-vials--no-kit.html:\n􀁸 “FAT DISSOLVER”\n􀁸 “The plant and vitamin based formulation dissolves localized cellulite and fat, tightens skin, and improves overall health.”\n􀁸 “Dissolve Fat & Cellulite - immediately breaks down fat cells (including cellulite) and speeds up metabolism.”\n􀁸 “Anti Aging – Centella Asiatica extract stimulates collagen, has anti-inflammatory properties, and is an excellent antioxidant”\n􀁸 “Increased Metabolism & Energy – Riboflavin (Vit B2) specializes in extracting energy from food while burning fat + functions as an antioxidant supporting the immune system, healthy skin, and hair.”\nOn your “Lipo Lab PPC Solution” webpage https:\u002F\u002Fwww.vividscientific.com\u002FLipoLab-Max-NO-KIT_p_57.html:\n􀁸 “Permanently dissolve fat and cellulite while increasing collagen and elastin with Lipo Lab's proprietary lipolysis formula.”\n􀁸 “Treatment with Lipo Lab produces rapid fat loss and prevents wrinkles and sagging as the fat layer shrinks.”\n􀁸 “Dissolve stubborn fat and cellulite”\n􀁸 “Increase metabolism”\n􀁸 “Boost energy levels”\n􀁸 “[S]odium deoxycholate breaks down the membranes of fat cells allowing phosphatidylcholine (PPC) to enter and dissolve fatty acid molecules.”\n􀁸 “L-carnitine, the third active ingredient, acts as a carrier molecule, facilitating the transport of fatty acids into the mitochondria, where they are converted into energy.”\n􀁸 “The active ingredients are naturally occurring molecules that dissolve fat and cellulite permanently. Treated fat cells can no longer store fat.”\nOn your “Neobella Extreme” webpage https:\u002F\u002Fwww.vividscientific.com\u002FNEOBELLAEXTREME-5-VIALS-NO-KIT_p_64.html:\n􀁸 “Target stubborn cellulite and fatty problem areas. . . . Results are permanent! Once the fat cells are dissolved, they are gone for good.”\n􀁸 “PERMANENT FAT REMOVAL + SKIN TIGHTENING IN ONE SYSTEM.”\n􀁸 “Fat dissolving injections provide a non-surgical, gentle method of sculpting the body gradually and artistically.”\n􀁸 “The main active ingredient is deoxycholic acid, a naturally occurring molecule that breaks down and destroys fat.”\nOn your “Deoxycholic Acid Booster” webpage https:\u002F\u002Fwww.vividscientific.com\u002Fdeoxycholic-acid-fat-dissolving-booster-10ml.html:\n􀁸 “DEOXYCHOLIC ACID FAT DISSOLVING BOOSTER contains the same deoxycholic acid formulation as KYBELLA.”\n􀁸 “The BOOSTER can be added to lipolysis serums (Neobella, LipoLab, etc.) to increase efficacy and accelerate results.”\nYour “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution,” “Neobella Extreme,” and “Deoxycholic Acid Booster” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “699226” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Vivid-Scientific LLC","vivid-scientific-llc-699226-03032025","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvivid-scientific-llc-699226-03032025","2026-10-26T08:10:28.93112+00:00","Warning Letter","Issued","2025-03-11","699226","Drugs","Lisa L. Currin","2026-08-19T16:59:25.361+00:00","Via Email","2025-03-03",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},3401,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-04-15T17:00:00Z\">04\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-18T04:00:00Z\">03\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblock-scientific-609533-03182021\">Block Scientific\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeremy Linder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Block Scientific\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>22 Sawgrass Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bellport\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11713\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@blockscientific.com\"> info@blockscientific.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 18, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.blockscientificstore.com on February 5, 2021. The FDA has observed that your website offers the “QUIKPACII COVID-19 ANTIBODY TEST KIT” (hereinafter referred to as “QCATK”) and the “Long Island Biotech COVID-19 Antigen Rapid Test (Colloidal Gold)” (which you also refer to as “[CoV19-AG] COVID-19 Antigen Rapid Test (Colloidal Gold) Long Island Biotech”) (hereinafter referred to as “LIBCART”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>QCATK and LIBCART are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraudscams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-frauds-cams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\n&nbsp; &nbsp; Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed)available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020) available at \u003Ca href=\"https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca>https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJeremy Linder\n\nBlock Scientific\n\n22 Sawgrass Drive\n\nBellport, NY 11713\n\nUnited States\n\ninfo@blockscientific.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: March 18, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.blockscientificstore.com on February 5, 2021. The FDA has observed that your website offers the “QUIKPACII COVID-19 ANTIBODY TEST KIT” (hereinafter referred to as “QCATK”) and the “Long Island Biotech COVID-19 Antigen Rapid Test (Colloidal Gold)” (which you also refer to as “[CoV19-AG] COVID-19 Antigen Rapid Test (Colloidal Gold) Long Island Biotech”) (hereinafter referred to as “LIBCART”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nQCATK and LIBCART are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your product(s) or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to immediately address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-frauds-cams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n___________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed)available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020) available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Block Scientific","block-scientific-609533-03182021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblock-scientific-609533-03182021","2026-10-26T08:08:06.46172+00:00","2021-04-15","609533","Medical Devices","Jeremy Linder","2026-08-20T03:11:43.538+00:00","2021-03-18",{"id":53,"raw":54,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":11,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},21684,[55,56,57,11,58,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faidance-scientific-inc-735346-10012026\">Aidance Scientific, Inc.\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Perry Antelman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aidance Scientific, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>184 Burnside Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woonsocket\u003C\u002Fspan>, \u003Cspan>RI\u003C\u002Fspan> \u003Cspan>02895\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@aidance.com\"> support@aidance.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 735346\u003C\u002Fp>\u003Cp>To Perry Antelman:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fwww.aidanceproducts.com\u002F, and provides you and opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “Terragen HG Formula” product on your website and available for purchase by clicking through to your Amazon storefront is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fwww.aidanceproducts.com\u002F and your Amazon storefront\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> in July 2026. Based on our review, “Terragen HG Formula” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of your website and Amazon storefront, “Terragen HG Formula” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and Amazon storefront, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>On the webpage www.aidanceproducts.com, consumers can “Shop by Condition” and select “Herpes,” which redirects to your Amazon storefront page for “Terragen HG Formula.”\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fwww.amazon.com\u002FTerragen-HG-Formula-Max-Sufferers\u002Fdp\u002FB06XT8CWCC\u002F?th=1:\u003C\u002Fp>\u003Cul>\u003Cli>“Genital sores treatment, outbreak support”\u003C\u002Fli>\u003Cli>“FAST RELIEF &amp; SOOTHING OINTMENT: . . . treatment cream relieves genital sores and symptoms including tingling, itch, irritation, redness, pain and inflammation. Provides relief quickly with natural, soothing ingredients. For men and woman, for daily use. Discreet packaging.”\u003C\u002Fli>\u003Cli>“EFFECTIVE PROTECTION &amp; HEALING: Terragen HG MAX . . . to protect the genital area from irritation and support natural healing.”\u003C\u002Fli>\u003Cli>“Product description . . .\u003Cbr>o Herpes Sores\u003Cbr>o Stinging Pain”\u003C\u002Fli>\u003Cli>On Drug Facts image:\u003Cbr>o “[R]elief of swelling and pain associated with genital sores.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Terragen HG Formula” is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>We recognize that your “Terragen HG Formula” product is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735346” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.amazon.com\u002Fstores\u002Fterrasil\u002Fpage\u002F3A25CD33-872F-419D-A8CB-B86731BDC2DA?lpasin=B06XT8CWCC&amp;ref=astbln&amp;storeref=blastdpbrandlogosto&amp;blgrdstatus=override\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nPerry Antelman\n\nRecipient Title\n\nPresident\n\nAidance Scientific, Inc.\n\n184 Burnside Ave\n\nWoonsocket, RI 02895\n\nUnited States\n\nsupport@aidance.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 735346\nTo Perry Antelman:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fwww.aidanceproducts.com\u002F, and provides you and opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “Terragen HG Formula” product on your website and available for purchase by clicking through to your Amazon storefront is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fwww.aidanceproducts.com\u002F and your Amazon storefront1 in July 2026. Based on our review, “Terragen HG Formula” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website and Amazon storefront, “Terragen HG Formula” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and Amazon storefront, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nOn the webpage www.aidanceproducts.com, consumers can “Shop by Condition” and select “Herpes,” which redirects to your Amazon storefront page for “Terragen HG Formula.”\nOn the webpage https:\u002F\u002Fwww.amazon.com\u002FTerragen-HG-Formula-Max-Sufferers\u002Fdp\u002FB06XT8CWCC\u002F?th=1:\n“Genital sores treatment, outbreak support”\n“FAST RELIEF & SOOTHING OINTMENT: . . . treatment cream relieves genital sores and symptoms including tingling, itch, irritation, redness, pain and inflammation. Provides relief quickly with natural, soothing ingredients. For men and woman, for daily use. Discreet packaging.”\n“EFFECTIVE PROTECTION & HEALING: Terragen HG MAX . . . to protect the genital area from irritation and support natural healing.”\n“Product description . . .\no Herpes Sores\no Stinging Pain”\nOn Drug Facts image:\no “[R]elief of swelling and pain associated with genital sores.”\n“Terragen HG Formula” is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nWe recognize that your “Terragen HG Formula” product is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735346” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_____________________\n1 https:\u002F\u002Fwww.amazon.com\u002Fstores\u002Fterrasil\u002Fpage\u002F3A25CD33-872F-419D-A8CB-B86731BDC2DA?lpasin=B06XT8CWCC&ref=astbln&storeref=blastdpbrandlogosto&blgrdstatus=override","Aidance Scientific, Inc.","aidance-scientific-inc-735346-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faidance-scientific-inc-735346-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","735346","Drugs Over-the-Counter Drugs","Perry Antelman","2026-10-14T12:32:41.467+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":63,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":93,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},21722,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-11T04:00:00Z\">09\u002F11\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnexcell-scientific-inc-730612-09112026\">NexCell Scientific Inc\u003C\u002Fa>","Center for Biologics Evaluation and Research","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-730612\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edwin Pinos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NexCell Scientific Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Hughes Ste 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618-2055\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ed@nexcellscientific.com\"> ed@nexcellscientific.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 11, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-730612\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Edwin Pinos:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between December 9 and 12, 2025, and between February 3 and 5, 2026. During the inspection, FDA documented that your company manufactures an umbilical cord blood-derived total nucleated cell (TNC) product, in multiple concentrations, for allogeneic use (hereinafter, “your product”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your product is also an unlicensed biological product in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211 in the manufacture of your product. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website www.nexcelllabs.com includes the following statements in its “What is Regenerative Medicine?” page, along with assurances that your company “uses exclusively umbilical cord derived cells”:\u003Cbr>o “Because of their ability to differentiate into cells that carry out the roles needed in a variety of organs, cell allografts are an essential regenerative tool. When these allografts are introduced into a damaged tissue or organ, they have the ability to evolve and carry out necessary functions, compensating for the damaged cells.”\u003Cbr>o “When injected into a damaged tissue, the cells specialize to carry out the necessary function of that particular area, improving symptoms and function.”\u003Cbr>o “[Mesenchymal stem cells] reduce the signal cells that promote inflammation… While this is another function that helps them avoid the immune response, it is also essential to the cells’ utility in chronic and autoimmune disease characterized by inflammation.”\u003Cbr>o Under the heading “How Stem Cells Work”, “Once in the affected area, the cells … begin to produce signaling proteins that work to regulate inflammation, aid in angiogenesis, and promote tissue repair.”\u003C\u002Fli>\u003Cli>The “Characterization of BioGenix® Allograft Products Independent Viability Study,” which you referenced during the FDA inspection as the “White Paper study” used to characterize your product, states:\u003Cbr>o On page 4, under the heading “Applications and Advantages”: “Research suggests that the use of mesenchymal and hematopoietic stem cells may offer potential benefits for musculoskeletal issues, wound injuries, cirrhosis of the liver, blood disorders, cardiovascular conditions, neurological disorders, and systemic and autoimmune diseases. A number of clinical trials have specifically targeted autoimmune issues, including multiple sclerosis, psoriasis, Crohn's disease, rheumatoid arthritis, lupus erythematosus, and others.” (citations omitted).\u003Cbr>o On page 10, under the heading “Discussion and Summation”: “Several research studies suggest that umbilical cord-derived allografts may have potential advantages for a range of indications, such as musculoskeletal disorders, modulation of immune responses, neurological conditions, liver cirrhosis, cardiovascular system issues, blood disorders, wound, and multiple variants of systemic or autoimmune disorders.” (citations omitted).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your product is a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, NexCell Scientific does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>Your product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical cord blood-derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your product is intended for use in the treatment of various diseases and conditions, such as inflammation, injuries, neurological conditions and liver cirrhosis, which are not basic functions of umbilical cord blood in the donor.\u003C\u002Fp>\u003Cp>In addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for their primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your product include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. \u003Cstrong>Failure to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> For example, your firm has not validated the manufacturing process for your product with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>2. \u003Cstrong>Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, your firm has not validated the aseptic process used to manufacture your product. Your product purports to be sterile and is expected to be sterile.\u003C\u002Fp>\u003Cp>3. \u003Cstrong>Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b).\u003C\u002Fstrong> For example, your firm has not established scientifically sound and appropriate specifications and test procedures to assure your product conforms to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, visual inspection, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>4. \u003Cstrong>Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed, as required by 21 CFR 211.192.\u003C\u002Fstrong> For example, between August 2023 and June 2025, \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of your finished product failed sterility testing. While you discarded these lots, you did not conduct investigations to determine the root cause(s) and whether other lots were impacted.\u003C\u002Fp>\u003Cp>5.\u003Cstrong> Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, your firm has not validated\u003Cbr>the cleaning and disinfection processes for your ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom or ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> where your product is manufactured.&nbsp;\u003C\u002Fp>\u003Cp>6. \u003Cstrong>Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv).\u003C\u002Fstrong> For example, your firm has not established an adequate program for environmental and personnel monitoring in the aseptic processing area where your product is manufactured. At the time of the inspection, environmental and personnel monitoring was not performed in association with each production shift.\u003C\u002Fp>\u003Cp>7. \u003Cstrong>Failure to establish an adequate quality control unit that has the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated, as required by 21 CFR 211.22(a).\u003C\u002Fstrong> For example, at the time of the inspection, your firm had one employee responsible for both manufacturing your product and quality unit responsibilities, with no independent quality unit in place.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated February 18, 2026, to FDA’s Form FDA-483 in detail. Your response is inadequate to address the violations noted above. For example, your response does not address your continued distribution of your product or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. Additionally, your corrective actions cannot be adequately evaluated because they lack supporting documentation.\u003C\u002Fp>\u003Cp>Further, for previously distributed lots of your product, your response does not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on lots that are still within expiry and were manufactured under the above-described violative conditions.\u003C\u002Fp>\u003Cp>Your response also does not adequately address your failure to have an Investigational New Drug (IND) in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. Your statement that you “are committed to achieving and maintaining compliance with 21 CFR Part 1271” does not resolve these issues, as your product does not meet the criteria to be regulated solely under section 361 of the PHS Act, as explained above. Your product is a drug and\u002For biological product, which is subject to premarket review and approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo, JD\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Edwin Pinos, co-owner\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-730612\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEdwin Pinos\n\nRecipient Title\n\nPresident\n\nNexCell Scientific Inc\n\n2 Hughes Ste 200\n\nIrvine, CA 92618-2055\n\nUnited States\n\ned@nexcellscientific.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nSeptember 11, 2026\nCBER 26-730612\nDear Edwin Pinos:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between December 9 and 12, 2025, and between February 3 and 5, 2026. During the inspection, FDA documented that your company manufactures an umbilical cord blood-derived total nucleated cell (TNC) product, in multiple concentrations, for allogeneic use (hereinafter, “your product”).\nThis letter is to advise you that your product is an unapproved new drug in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your product is also an unlicensed biological product in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211 in the manufacture of your product. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your product into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, your product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For is intended to affect the structure or function of the body. For example:\nYour website www.nexcelllabs.com includes the following statements in its “What is Regenerative Medicine?” page, along with assurances that your company “uses exclusively umbilical cord derived cells”:\no “Because of their ability to differentiate into cells that carry out the roles needed in a variety of organs, cell allografts are an essential regenerative tool. When these allografts are introduced into a damaged tissue or organ, they have the ability to evolve and carry out necessary functions, compensating for the damaged cells.”\no “When injected into a damaged tissue, the cells specialize to carry out the necessary function of that particular area, improving symptoms and function.”\no “[Mesenchymal stem cells] reduce the signal cells that promote inflammation… While this is another function that helps them avoid the immune response, it is also essential to the cells’ utility in chronic and autoimmune disease characterized by inflammation.”\no Under the heading “How Stem Cells Work”, “Once in the affected area, the cells … begin to produce signaling proteins that work to regulate inflammation, aid in angiogenesis, and promote tissue repair.”\nThe “Characterization of BioGenix® Allograft Products Independent Viability Study,” which you referenced during the FDA inspection as the “White Paper study” used to characterize your product, states:\no On page 4, under the heading “Applications and Advantages”: “Research suggests that the use of mesenchymal and hematopoietic stem cells may offer potential benefits for musculoskeletal issues, wound injuries, cirrhosis of the liver, blood disorders, cardiovascular conditions, neurological disorders, and systemic and autoimmune diseases. A number of clinical trials have specifically targeted autoimmune issues, including multiple sclerosis, psoriasis, Crohn's disease, rheumatoid arthritis, lupus erythematosus, and others.” (citations omitted).\no On page 10, under the heading “Discussion and Summation”: “Several research studies suggest that umbilical cord-derived allografts may have potential advantages for a range of indications, such as musculoskeletal disorders, modulation of immune responses, neurological conditions, liver cirrhosis, cardiovascular system issues, blood disorders, wound, and multiple variants of systemic or autoimmune disorders.” (citations omitted).\nTherefore, your product is a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, NexCell Scientific does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nYour product fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your umbilical cord blood-derived product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your product is intended for use in the treatment of various diseases and conditions, such as inflammation, injuries, neurological conditions and liver cirrhosis, which are not basic functions of umbilical cord blood in the donor.\nIn addition, your product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for their primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.1 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your product is not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your product include, but are not limited to, the following:\n1. Failure to establish adequate written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a). For example, your firm has not validated the manufacturing process for your product with respect to identity, strength, quality, and purity.\n2. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, your firm has not validated the aseptic process used to manufacture your product. Your product purports to be sterile and is expected to be sterile.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b). For example, your firm has not established scientifically sound and appropriate specifications and test procedures to assure your product conforms to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, visual inspection, and (b)(4).\n4. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has already been distributed, as required by 21 CFR 211.192. For example, between August 2023 and June 2025, (b)(4) lots of your finished product failed sterility testing. While you discarded these lots, you did not conduct investigations to determine the root cause(s) and whether other lots were impacted.\n5. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, your firm has not validated\nthe cleaning and disinfection processes for your ISO (b)(4) cleanroom or ISO (b)(4) where your product is manufactured.\n6. Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv). For example, your firm has not established an adequate program for environmental and personnel monitoring in the aseptic processing area where your product is manufactured. At the time of the inspection, environmental and personnel monitoring was not performed in association with each production shift.\n7. Failure to establish an adequate quality control unit that has the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated, as required by 21 CFR 211.22(a). For example, at the time of the inspection, your firm had one employee responsible for both manufacturing your product and quality unit responsibilities, with no independent quality unit in place.\nResponse to the Form FDA-483\nWe have reviewed your response, dated February 18, 2026, to FDA’s Form FDA-483 in detail. Your response is inadequate to address the violations noted above. For example, your response does not address your continued distribution of your product or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. Additionally, your corrective actions cannot be adequately evaluated because they lack supporting documentation.\nFurther, for previously distributed lots of your product, your response does not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on lots that are still within expiry and were manufactured under the above-described violative conditions.\nYour response also does not adequately address your failure to have an Investigational New Drug (IND) in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. Your statement that you “are committed to achieving and maintaining compliance with 21 CFR Part 1271” does not resolve these issues, as your product does not meet the criteria to be regulated solely under section 361 of the PHS Act, as explained above. Your product is a drug and\u002For biological product, which is subject to premarket review and approval requirements.\nConclusion\nNeither this letter nor the observations noted on Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your product is in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo, JD\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: Edwin Pinos, co-owner\n(b)(4), (b)(6)\n(b)(4), (b)(6)\n(b)(4), (b)(6)\n___________________________\n1 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","NexCell Scientific Inc","nexcell-scientific-inc-730612-09112026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnexcell-scientific-inc-730612-09112026","2026-11-03T01:02:17.615107+00:00","2026-09-22","730612","Biologics","Edwin Pinos","2026-10-14T12:36:37.035+00:00","Via UPS and EMAIL","CBER 26-730612","2026-09-11",{"id":96,"raw":97,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":23,"posted_date":110,"marcs_cms_no":111,"product_type":26,"closeout_date":19,"issuing_office":101,"recipient_name":112,"body_fetched_at":113,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},2722,[98,99,100,101,102,13,13,13],"\u003Ctime datetime=\"2022-04-26T13:20:00Z\">04\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-17T04:00:00Z\">03\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitae-enim-vitae-scientific-inc-620576-03172022\">Vitae Enim Vitae Scientific Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Charles L. Cavallino\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vitae Enim Vitae Scientific Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3030 Bunker Hill St., Ste. 203\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:charlie@vevscientific.com\"> charlie@vevscientific.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 17, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Cavallino:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Vitae Enim Vitae Scientific Inc., FEI 3014384422, at 3030 Bunker Hill St., Ste 203, San Diego, California, from September 13 to 22, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Smoke Study Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your procedures did not include a requirement for smoke studies to be performed in ISO 5 classified areas. You also failed to perform smoke studies prior to the inspection. You performed a cursory smoke study during the inspection on September 21, 2021, only after questions from the investigator. You have been manufacturing and distributing since January 2020 without assurance your aseptic processing is designed to protect sterile drug product and its containers and closures.\u003C\u002Fp>\n\n\u003Cp>Thorough smoke studies are essential to evaluate the critical ISO 5 aseptic processing areas and the effects of interventions on unidirectional airflow, and to ensure needed design remediations.\u003C\u002Fp>\n\n\u003Cp>We also note that there were multiple design deficiencies in both your ISO 5 cabinet and its aseptic processing line which represent fundamental contamination risks. For example:\u003C\u002Fp>\n\n\u003Cp>• The equipment design, layout, and operating practices of the aseptic processing line, its filling cabinet and the cleanroom pose hazards to sterile products you manufacture.\u003Cbr>\n• The HEPA-filtered airflow is insufficient to ensure robust ISO 5 aseptic conditions throughout the aseptic processing line.\u003Cbr>\n• Your filling machine frequently alarmed during aseptic processing. You explained some of these high priority alarms may be due to air disrupting load balance cells used for weight measurement. You failed to evaluate the impact of the airflow on your aseptic processing line.\u003C\u002Fp>\n\n\u003Cp>In addition, inadequate aseptic processing operator gowning (e.g., some components are not sterile) practices also pose a significant contamination hazard in your aseptic processing operation.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to provide a protocol or a clear description of the extremely limited static smoke study you conducted during the inspection. Your smoke study was not performed under dynamic conditions and did not evaluate personnel interventions. The study also lacked adequate visualization of airflow in the ISO 5 area, including filling, stoppering, and capping areas. Based on our review of your brief recording, we did not observe “unidirectional airflow and sweeping action away from product” as reported in your response to our information request dated February 1, 2022.\u003C\u002Fp>\n\n\u003Cp>In addition, the revised procedure you submitted does not require smoke studies to be performed under dynamic conditions and only includes \u003Cstrong>(b)(4)\u003C\u002Fstrong> study as part of the HEPA requalification. In your response to the information request dated February 1, 2022, you stated that smoke studies will not be conducted and that you intend to rely on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> HEPA filter tests, \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration of the magnehelic gauges, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification checks which you believe replace the need to show unidirectional airflow on the aseptic processing line. This conclusion is flawed as these activities do not provide an assessment of unidirectional airflow protection of the aseptic processing line and are not a substitute for smoke studies.\u003C\u002Fp>\n\n\u003Cp>Sterile products are exposed in the ISO 5 area, and therefore vulnerable to contamination. Your aseptic manufacturing process should be designed, qualified, and operations executed, to prevent contamination. Flaws in the design of cleanrooms and aseptic processing lines can lead to an influx of contamination into the critical ISO 5 aseptic processing area and pose a significant hazard to product sterility.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Process Simulation Deficiencies\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to establish a procedure which outlines specific training for personnel responsible for the microbiological examination of media fill vials. You also did not require qualified individuals (e.g., microbiologist) to inspect incubated media fill vials for microbial growth.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You committed to revise procedures, train employees, and have appropriate personnel from a microbiology laboratory “inspect the next set of media fills for possible contamination.” However, you failed to perform a full assessment of your media fill program and you did not evaluate the impact of untrained personnel on the reliability of past media fill results. You did not provide detailed information regarding the content of your training program and implementation dates for your revised procedures. Furthermore, you failed to indicate if a microbiologist with the appropriate combination of education, training, and experience will provide continuous oversight over media fill vial examinations as a permanent standard operating procedure in the future.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>\n&nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003Cbr>\n&nbsp; o Personnel gowning standards\u003Cbr>\n• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe how you will remediate the design and control of your aseptic processing operation. In particular, include comprehensive improvements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003Cbr>\n• Your plan to conduct smoke studies after you comprehensively remediate the design flaws in your aseptic operation under static and dynamic conditions. Regarding the latter, include comprehensive evaluations of aseptic interventions, operator positioning, and airflow impact within the aseptic processing area. Commit to provide full records of smoke studies to this office upon completion, including both static and dynamic smoke studies.\u003Cbr>\n• A comprehensive independent review of your media fill program.\u003Cbr>\n• An evaluation of the impact of unqualified personnel performing microbiological examinations of media fill units, including an analysis of how unqualified staff can undermine the ability to detect contaminated units\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your environmental monitoring program is deficient. You did not perform active viable air sampling during aseptic processing. In addition, your environmental monitoring procedures for viable and non-viable sampling lacked adequate information on:\u003Cbr>\n• Alert levels\u003Cbr>\n• Frequency of sampling\u003Cbr>\n• When the samples are taken\u003Cbr>\n• Duration of sampling\u003Cbr>\n• Sample size\u003Cbr>\n• Responding to deviations from alert levels\u003Cbr>\n• Routine review of environmental data\u003Cbr>\n• Evaluation of trends.\u003C\u002Fp>\n\n\u003Cp>Vigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment and ancillary classified areas. Adverse trends and potential routes of contamination should be identified promptly, allowing for implementation of appropriate follow-up measures to prevent contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to comprehensively address your environmental monitoring deficiencies and the effect of your deficient practices on the quality of distributed drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\u003Cbr>\n&nbsp; o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\u003Cbr>\n&nbsp; o A risk assessment based on a retrospective review of personnel and environmental monitoring data since you initiated sterile manufacturing in November 2019.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. You firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate oversight of contract testing laboratory\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your Quality Unit (QU) failed to provide adequate oversight of your contract testing laboratory. For example, you failed to ensure analytical and microbiological test methods used by your contract testing laboratory for sterile drug products were validated (or verified). Your contract testing laboratory performed numerous raw material tests, as well as release and stability tests for your sterile drug products (e.g., assay, particulate matter, endotoxin, and sterility). Furthermore, you failed to evaluate chemical and microbiological method validation and verification as part of the supplier quality audit report of the contract laboratory. In the quality agreement with your contract laboratory, you accepted responsibility for overseeing method validation and verification, but you failed to perform this role.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for ensuring the test methods used and data obtained by your contract testing laboratories are accurate and reliable. The release of drug products without assurance they have the identity, strength, quality, and purity they purport or are represented to possess could result in undetected hazards to patients.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You acknowledged you did not have the method verification and validation records, and you requested the documents from your contract testing laboratory. In addition, you stated you would move testing in-house that you “determine to be critical” to your operations. However, you did not provide further details of your laboratory capabilities for testing. Your response stated a change control and risk assessment would be developed for these new activities, but you did not provide timelines for completion.\u003C\u002Fp>\n\n\u003Cp>The FDA cited a similar observation in your February 2019 inspection. Your March 2019 response committed to ensure that future contract testing laboratories would have verified USP procedures or appropriate method validation.\u003C\u002Fp>\n\n\u003Cp>Without appropriate validated (or, as appropriate, verified) methods, you cannot make appropriate batch release decisions, stability decisions, and other decisions that are fundamental to an ongoing assurance of quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• An independent, comprehensive assessment of all contract laboratory methods, equipment, documentation, and analyst competencies. The assessment should include an evaluation of the reliability of the data generated by your contract testing laboratories. Based on this review:\u003Cbr>\n&nbsp; o Provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n&nbsp; o An assessment of the impact of these findings on your drug products.\u003Cbr>\n• A list of chemical and microbial specifications for both release and stability test, including test methods, used to analyze each batch of your drug products before a batch disposition decision. In addition, for each provide the following:\u003Cbr>\n&nbsp; o Your assessment for each method used to test a compendial article or substance to determine if it follows the compendial test procedures.\u003Cbr>\n&nbsp; o For each method found to differ from the compendial method, provide your detailed plan to determine whether the method is equivalent or better than the compendial method and the date by which this activity will be completed.\u003Cbr>\n&nbsp; o A list of method verification and validation studies with report approval dates for each sterile and non-sterile drug product.\u003Cbr>\n• A summary of your program for qualifying and overseeing contract facilities that test or perform other CGMP functions on your behalf. Provide documentation of roles and responsibilities for each supplier, including packagers, labelers, distributors, contract manufacturers, contract testing laboratories, or other activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate qualification of suppliers\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU failed to adequately evaluate the potential quality impact of a new sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier on your sterile drug products. For example, you failed to adequately qualify your new supplier and your change control form does not indicate that you performed water testing prior to accepting the supplier for this drug component. Furthermore, you did not adequately evaluate the removal of pH from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification and its impact on your drug products.\u003C\u002Fp>\n\n\u003Cp>Without appropriate change management, you lack assurance that product quality is not adversely affected.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You committed to revise your change management procedures and perform a retrospective assessment of the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplied by your vendor. However, you failed to perform a retrospective assessment of other supplied materials that may impact product quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes (including supplier changes) are justified, reviewed, and approved by your quality assurance unit. Your change management program should also include provisions for determining change effectiveness (e.g., placing lots on stability when there are significant changes to the operations).\u003Cbr>\n• A retrospective assessment of your change in supplier for sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This should include, but not be limited to the removal of pH from your sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification.\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You lacked adequate investigations, including insufficient root cause determination and failure to expand investigations to all potentially affected batches.\u003C\u002Fp>\n\n\u003Cp>For example, your deviation report stated, “when transferring \u003Cstrong>(b)(4)\u003C\u002Fstrong> from formulation vessel to the ISO 5 filling space… the ink from the tubing started leeching into the solution.” It also stated, “It seems the ink, or the process by which the ink is applied to tubing changed.” Although you rejected the sub-batch, the investigation lacked a determination of the root cause. Your investigation also lacked a well justified scope, including a review of other batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and other drug products manufactured using the same tubing that may have been adversely affected by this chemical contamination. The investigation also lacked information relating to the toxicity of this foreign contaminant in parenteral products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to evaluate the potential of ink leaching into previously manufactured batches of drug products. You committed to perform a risk assessment to evaluate the change in transfer tubing. However, you failed to provide your risk assessment in your subsequent responses.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A thorough and complete risk assessment that evaluates how leaching ink may have affected the quality of your drug products. Include the following:\u003Cbr>\n&nbsp; o A list of products, including batch numbers and dates manufactured which used the tubing\u003Cbr>\n&nbsp; o The chemical name, composition, and toxicity of the contaminant that leached into the product\u003Cbr>\n• A detailed description of your drug product transfer process prior to implementation of the CAPA. Explain how ink from the outside of the transfer tubing came in contact with the drug product solution and allowed ink to leach into that solution.\u003Cbr>\n• A comprehensive assessment of the overall system for investigating deviations and discrepancies. Provide a detailed action plan to remediate this system to include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003Cbr>\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product (21 CFR 211.110(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately inspect your sterile drug products for visible defects and contamination.\u003C\u002Fp>\n\n\u003Cp>Your limited post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, only a small number of vials were inspected, and they were not inspected against solid color backgrounds (i.e., white and black) to identify visible defects such as particulates and cloudiness. You also lacked procedures for this visual inspection activity.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Although you committed to create a visual inspection procedure, you did not provide details or interim controls until your remediated program is in place. You also did not perform a risk assessment for products already released. Furthermore, you did not provide details as to how your program would ensure personnel are able to reliably identify visible defects.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A formalized 100% visual inspection program designed to detect particulate contamination and other visible defects. Your program should detail the inspection process, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\u003Cbr>\n• A retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\u003Cbr>\n• Perform a visual inspection of retain samples for all batches already in distribution and provide the results.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Product Recall and Future Manufacturing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge you initiated a recall of all products intended to be sterile that are within expiry after discussions with the FDA.\u003C\u002Fp>\n\n\u003Cp>Notify this office if you plan to resume production and distribution of sterile products, so that the FDA may conduct a follow-up inspection. This notification should occur only after the violations at your firm have been fully remediated and verified by an independent third party (see CGMP consultant paragraph below). It is essential that this remediation be supported by well-designed equipment and facilities, robust processes, and satisfactory qualification and validation studies.\u003C\u002Fp>\n\n\u003Cp>We note your recent proposal dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, regarding \u003Cstrong>(b)(4)\u003C\u002Fstrong> of previously manufactured products in your control; however, additional information is required to establish the scientific basis of your approach. This information should include details such as, and not limited to, stability (including integrity) of container-closure systems and formulations for each product, as well as qualification and validation studies.\u003C\u002Fp>\n\n\u003Cp>After receipt of this letter contact this office to schedule a meeting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See the FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Process Validation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See the FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at Process Validation: General Principles and Practices | FDA\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See the FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection, dated February 2 to 27, 2019, the FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response.\u003C\u002Fp>\n\n\u003Cp>Repeated failures to address deficient operations demonstrate that executive management oversight and control is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, the FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows the FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier 620576.\u003C\u002Fp>\n\n\u003Cp>If you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Charles L. Cavallino\n\nRecipient Title\n\nManaging Director\n\nVitae Enim Vitae Scientific Inc.\n\n3030 Bunker Hill St., Ste. 203\n\nSan Diego, CA 92109\n\nUnited States\n\ncharlie@vevscientific.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMarch 17, 2022\n\nDear Mr. Cavallino:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Vitae Enim Vitae Scientific Inc., FEI 3014384422, at 3030 Bunker Hill St., Ste 203, San Diego, California, from September 13 to 22, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nSmoke Study Deficiencies\n\nYour procedures did not include a requirement for smoke studies to be performed in ISO 5 classified areas. You also failed to perform smoke studies prior to the inspection. You performed a cursory smoke study during the inspection on September 21, 2021, only after questions from the investigator. You have been manufacturing and distributing since January 2020 without assurance your aseptic processing is designed to protect sterile drug product and its containers and closures.\n\nThorough smoke studies are essential to evaluate the critical ISO 5 aseptic processing areas and the effects of interventions on unidirectional airflow, and to ensure needed design remediations.\n\nWe also note that there were multiple design deficiencies in both your ISO 5 cabinet and its aseptic processing line which represent fundamental contamination risks. For example:\n\n• The equipment design, layout, and operating practices of the aseptic processing line, its filling cabinet and the cleanroom pose hazards to sterile products you manufacture.\n\n• The HEPA-filtered airflow is insufficient to ensure robust ISO 5 aseptic conditions throughout the aseptic processing line.\n\n• Your filling machine frequently alarmed during aseptic processing. You explained some of these high priority alarms may be due to air disrupting load balance cells used for weight measurement. You failed to evaluate the impact of the airflow on your aseptic processing line.\n\nIn addition, inadequate aseptic processing operator gowning (e.g., some components are not sterile) practices also pose a significant contamination hazard in your aseptic processing operation.\n\nYour response is inadequate. You failed to provide a protocol or a clear description of the extremely limited static smoke study you conducted during the inspection. Your smoke study was not performed under dynamic conditions and did not evaluate personnel interventions. The study also lacked adequate visualization of airflow in the ISO 5 area, including filling, stoppering, and capping areas. Based on our review of your brief recording, we did not observe “unidirectional airflow and sweeping action away from product” as reported in your response to our information request dated February 1, 2022.\n\nIn addition, the revised procedure you submitted does not require smoke studies to be performed under dynamic conditions and only includes (b)(4) study as part of the HEPA requalification. In your response to the information request dated February 1, 2022, you stated that smoke studies will not be conducted and that you intend to rely on the (b)(4) HEPA filter tests, (b)(4) calibration of the magnehelic gauges, and (b)(4) verification checks which you believe replace the need to show unidirectional airflow on the aseptic processing line. This conclusion is flawed as these activities do not provide an assessment of unidirectional airflow protection of the aseptic processing line and are not a substitute for smoke studies.\n\nSterile products are exposed in the ISO 5 area, and therefore vulnerable to contamination. Your aseptic manufacturing process should be designed, qualified, and operations executed, to prevent contamination. Flaws in the design of cleanrooms and aseptic processing lines can lead to an influx of contamination into the critical ISO 5 aseptic processing area and pose a significant hazard to product sterility.\n\nProcess Simulation Deficiencies\n\nYou failed to establish a procedure which outlines specific training for personnel responsible for the microbiological examination of media fill vials. You also did not require qualified individuals (e.g., microbiologist) to inspect incubated media fill vials for microbial growth.\n\nYour response is inadequate. You committed to revise procedures, train employees, and have appropriate personnel from a microbiology laboratory “inspect the next set of media fills for possible contamination.” However, you failed to perform a full assessment of your media fill program and you did not evaluate the impact of untrained personnel on the reliability of past media fill results. You did not provide detailed information regarding the content of your training program and implementation dates for your revised procedures. Furthermore, you failed to indicate if a microbiologist with the appropriate combination of education, training, and experience will provide continuous oversight over media fill vial examinations as a permanent standard operating procedure in the future.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\n\no Personnel gowning standards\n\n• A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe how you will remediate the design and control of your aseptic processing operation. In particular, include comprehensive improvements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n\n• Your plan to conduct smoke studies after you comprehensively remediate the design flaws in your aseptic operation under static and dynamic conditions. Regarding the latter, include comprehensive evaluations of aseptic interventions, operator positioning, and airflow impact within the aseptic processing area. Commit to provide full records of smoke studies to this office upon completion, including both static and dynamic smoke studies.\n\n• A comprehensive independent review of your media fill program.\n\n• An evaluation of the impact of unqualified personnel performing microbiological examinations of media fill units, including an analysis of how unqualified staff can undermine the ability to detect contaminated units\n\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\nYour environmental monitoring program is deficient. You did not perform active viable air sampling during aseptic processing. In addition, your environmental monitoring procedures for viable and non-viable sampling lacked adequate information on:\n\n• Alert levels\n\n• Frequency of sampling\n\n• When the samples are taken\n\n• Duration of sampling\n\n• Sample size\n\n• Responding to deviations from alert levels\n\n• Routine review of environmental data\n\n• Evaluation of trends.\n\nVigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment and ancillary classified areas. Adverse trends and potential routes of contamination should be identified promptly, allowing for implementation of appropriate follow-up measures to prevent contamination.\n\nYour response is inadequate because you failed to comprehensively address your environmental monitoring deficiencies and the effect of your deficient practices on the quality of distributed drug products.\n\nIn response to this letter, provide:\n\n• A comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\n\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\n\no A risk assessment based on a retrospective review of personnel and environmental monitoring data since you initiated sterile manufacturing in November 2019.\n\n3. You firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nInadequate oversight of contract testing laboratory\n\nYour Quality Unit (QU) failed to provide adequate oversight of your contract testing laboratory. For example, you failed to ensure analytical and microbiological test methods used by your contract testing laboratory for sterile drug products were validated (or verified). Your contract testing laboratory performed numerous raw material tests, as well as release and stability tests for your sterile drug products (e.g., assay, particulate matter, endotoxin, and sterility). Furthermore, you failed to evaluate chemical and microbiological method validation and verification as part of the supplier quality audit report of the contract laboratory. In the quality agreement with your contract laboratory, you accepted responsibility for overseeing method validation and verification, but you failed to perform this role.\n\nYour QU is responsible for ensuring the test methods used and data obtained by your contract testing laboratories are accurate and reliable. The release of drug products without assurance they have the identity, strength, quality, and purity they purport or are represented to possess could result in undetected hazards to patients.\n\nYour response is inadequate. You acknowledged you did not have the method verification and validation records, and you requested the documents from your contract testing laboratory. In addition, you stated you would move testing in-house that you “determine to be critical” to your operations. However, you did not provide further details of your laboratory capabilities for testing. Your response stated a change control and risk assessment would be developed for these new activities, but you did not provide timelines for completion.\n\nThe FDA cited a similar observation in your February 2019 inspection. Your March 2019 response committed to ensure that future contract testing laboratories would have verified USP procedures or appropriate method validation.\n\nWithout appropriate validated (or, as appropriate, verified) methods, you cannot make appropriate batch release decisions, stability decisions, and other decisions that are fundamental to an ongoing assurance of quality.\n\nIn response to this letter, provide:\n\n• An independent, comprehensive assessment of all contract laboratory methods, equipment, documentation, and analyst competencies. The assessment should include an evaluation of the reliability of the data generated by your contract testing laboratories. Based on this review:\n\no Provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\no An assessment of the impact of these findings on your drug products.\n\n• A list of chemical and microbial specifications for both release and stability test, including test methods, used to analyze each batch of your drug products before a batch disposition decision. In addition, for each provide the following:\n\no Your assessment for each method used to test a compendial article or substance to determine if it follows the compendial test procedures.\n\no For each method found to differ from the compendial method, provide your detailed plan to determine whether the method is equivalent or better than the compendial method and the date by which this activity will be completed.\n\no A list of method verification and validation studies with report approval dates for each sterile and non-sterile drug product.\n\n• A summary of your program for qualifying and overseeing contract facilities that test or perform other CGMP functions on your behalf. Provide documentation of roles and responsibilities for each supplier, including packagers, labelers, distributors, contract manufacturers, contract testing laboratories, or other activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\n\nInadequate qualification of suppliers\n\nYour QU failed to adequately evaluate the potential quality impact of a new sterile (b)(4) supplier on your sterile drug products. For example, you failed to adequately qualify your new supplier and your change control form does not indicate that you performed water testing prior to accepting the supplier for this drug component. Furthermore, you did not adequately evaluate the removal of pH from your (b)(4) specification and its impact on your drug products.\n\nWithout appropriate change management, you lack assurance that product quality is not adversely affected.\n\nYour response is inadequate. You committed to revise your change management procedures and perform a retrospective assessment of the sterile (b)(4) supplied by your vendor. However, you failed to perform a retrospective assessment of other supplied materials that may impact product quality.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedures to ensure changes (including supplier changes) are justified, reviewed, and approved by your quality assurance unit. Your change management program should also include provisions for determining change effectiveness (e.g., placing lots on stability when there are significant changes to the operations).\n\n• A retrospective assessment of your change in supplier for sterile (b)(4). This should include, but not be limited to the removal of pH from your sterile (b)(4) specification.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou lacked adequate investigations, including insufficient root cause determination and failure to expand investigations to all potentially affected batches.\n\nFor example, your deviation report stated, “when transferring (b)(4) from formulation vessel to the ISO 5 filling space… the ink from the tubing started leeching into the solution.” It also stated, “It seems the ink, or the process by which the ink is applied to tubing changed.” Although you rejected the sub-batch, the investigation lacked a determination of the root cause. Your investigation also lacked a well justified scope, including a review of other batches of (b)(4) and other drug products manufactured using the same tubing that may have been adversely affected by this chemical contamination. The investigation also lacked information relating to the toxicity of this foreign contaminant in parenteral products.\n\nYour response is inadequate because you failed to evaluate the potential of ink leaching into previously manufactured batches of drug products. You committed to perform a risk assessment to evaluate the change in transfer tubing. However, you failed to provide your risk assessment in your subsequent responses.\n\nIn response to this letter, provide:\n\n• A thorough and complete risk assessment that evaluates how leaching ink may have affected the quality of your drug products. Include the following:\n\no A list of products, including batch numbers and dates manufactured which used the tubing\n\no The chemical name, composition, and toxicity of the contaminant that leached into the product\n\n• A detailed description of your drug product transfer process prior to implementation of the CAPA. Explain how ink from the outside of the transfer tubing came in contact with the drug product solution and allowed ink to leach into that solution.\n\n• A comprehensive assessment of the overall system for investigating deviations and discrepancies. Provide a detailed action plan to remediate this system to include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\n\n5. Your firm failed to establish and follow adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product (21 CFR 211.110(a)).\n\nYou failed to adequately inspect your sterile drug products for visible defects and contamination.\n\nYour limited post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, only a small number of vials were inspected, and they were not inspected against solid color backgrounds (i.e., white and black) to identify visible defects such as particulates and cloudiness. You also lacked procedures for this visual inspection activity.\n\nYour response is inadequate. Although you committed to create a visual inspection procedure, you did not provide details or interim controls until your remediated program is in place. You also did not perform a risk assessment for products already released. Furthermore, you did not provide details as to how your program would ensure personnel are able to reliably identify visible defects.\n\nIn response to this letter, provide:\n\n• A formalized 100% visual inspection program designed to detect particulate contamination and other visible defects. Your program should detail the inspection process, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\n\n• A retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\n\n• Perform a visual inspection of retain samples for all batches already in distribution and provide the results.\n\nProduct Recall and Future Manufacturing\n\nWe acknowledge you initiated a recall of all products intended to be sterile that are within expiry after discussions with the FDA.\n\nNotify this office if you plan to resume production and distribution of sterile products, so that the FDA may conduct a follow-up inspection. This notification should occur only after the violations at your firm have been fully remediated and verified by an independent third party (see CGMP consultant paragraph below). It is essential that this remediation be supported by well-designed equipment and facilities, robust processes, and satisfactory qualification and validation studies.\n\nWe note your recent proposal dated (b)(4), regarding (b)(4) of previously manufactured products in your control; however, additional information is required to establish the scientific basis of your approach. This information should include details such as, and not limited to, stability (including integrity) of container-closure systems and formulations for each product, as well as qualification and validation studies.\n\nAfter receipt of this letter contact this office to schedule a meeting.\n\nAdditional Guidance on Aseptic Processing\n\nSee the FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nAdditional Guidance on Process Validation\n\nSee the FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at Process Validation: General Principles and Practices | FDA\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See the FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\n\nRepeat Observations at Facility\n\nIn a previous inspection, dated February 2 to 27, 2019, the FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response.\n\nRepeated failures to address deficient operations demonstrate that executive management oversight and control is inadequate.\n\nCGMP Consultant\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, the FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows the FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your response with unique identifier 620576.\n\nIf you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV","Vitae Enim Vitae Scientific Inc.","vitae-enim-vitae-scientific-inc-620576-03172022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitae-enim-vitae-scientific-inc-620576-03172022","2026-10-26T08:10:28.352061+00:00","2022-04-26","620576","Mr. Charles L. Cavallino","2026-08-20T01:58:43.152+00:00","2022-03-17",{"id":116,"raw":117,"subject":122,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":43,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":130,"posted_date":131,"marcs_cms_no":132,"product_type":133,"closeout_date":134,"issuing_office":121,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},3041,[118,119,120,121,122,13,123,13],"\u003Ctime datetime=\"2021-11-09T14:20:00Z\">11\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-13T04:00:00Z\">10\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquicksilver-scientific-612476-10132021\">Quicksilver Scientific\u003C\u002Fa>","Office of Human and Animal Food Operations Division West 4","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquicksilver-scientific-inc-612476-09302024\">\u003Ctime datetime=\"2024-10-03T04:00:00Z\">10\u002F03\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher W. Shade, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Quicksilver Scientific\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1960 Cherry Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Louisville\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80027\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division West 4\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 13, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Ref: CMS Case #612476\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Shade:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the internet address www.quicksilverscientific.com in June and September 2021 and has determined that you take orders there for the products Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Nanoemulsified CoQ10\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>QuickSilverScientific.com\u002FBlog\u003C\u002Fp>\n\n\u003Cp>• \u003Cem>\u003Cstrong>Eight Ways to a Healthy Heart,\u003C\u002Fstrong>\u003C\u002Fem> (which references the ingredient Coenzyme Q10 contained in the product Nanoemulsified CoQ10)\u003Cbr>\n\u003Cbr>\n “study on CoQ10 . . . found a 44% reduction in death from heart disease in heart failure patients supplemented with CoQ10, and a 42% reduction in death from any cause.”\u003C\u002Fp>\n\n\u003Cp>• \u003Cem>\u003Cstrong>Holiday Hangovers:\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>After All That Partying, Which Nutrients Do You Need the Most\u003C\u002Fem> (which references the ingredient Coenzyme Q10 contained in the product Nanoemulsified CoQ10)\u003C\u002Fp>\n\n\u003Cp>o \u003Cstrong>“Feed Your Mitochondria with CoEnzyme Q10\u003C\u002Fstrong> . . .—breakthrough research into these tiny energy powerhouses that stud our cells has now connected them to . . . our ability to . . . directly fight pathogens and bacteria. If there is one nutrient that is essential for mitochondria, it is CoQ10.”\u003C\u002Fp>\n\n\u003Cp>o “Alcohol can deplete CoQ10. Supplementing with this nutrient has been found to protect the liver from oxidative stress and improve inflammation associated with fatty infiltration of the liver. It has also been shown to protect the liver from alcohol-related damage.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cat’s Claw Elite\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>QuickSilverScientific.com\u002FBlog\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>6 Tips for having a Healthy, Happy Holiday Season\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>o “Vitamin D [an ingredient in Cat’s Claw Elite] supports immunity by increasing the activity of monocytes and macrophages, immune cells that directly fight pathogens, and by increasing the production of antimicrobial peptides . . ..”\u003C\u002Fp>\n\n\u003Cp>o “Monolaurin [an ingredient in Cat’s Claw Elite] . . . has immune modulating properties and antimicrobial effects against a variety of bacteria and viruses.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Nanoemulsified Milk Thistle\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>QuickSilverScientific.com\u002FBlog\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>6 Tips for having a Healthy, Happy Holiday Season\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>o “Milk thistle [an ingredient in Nanoemulsified Milk Thistle] . . . protects liver cells from the harmful effects of alcohol . . . Supplementing with milk thistle after a particularly indulgent holiday party may ease your discomfort and help you recover faster.”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Liposomal GABA with L-Theanine\u003C\u002Fstrong> product web page:\u003C\u002Fp>\n\n\u003Cp>• “Stress and mental strain can . . . impair sleep. Return to a state of balance with . . . GABA + L-theanine . . ..”\u003C\u002Fp>\n\n\u003Cp>Your products Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine products fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations Division West 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nChristopher W. Shade, PhD\n\nQuicksilver Scientific\n\n1960 Cherry Street\n\nLouisville, CO 80027\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division West 4\n\nUnited States\n\nOctober 13, 2021\n\nWARNING LETTER\n\nRef: CMS Case #612476\n\nDear Dr. Shade:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the internet address www.quicksilverscientific.com in June and September 2021 and has determined that you take orders there for the products Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine. The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nNanoemulsified CoQ10\n\nQuickSilverScientific.com\u002FBlog\n\n• Eight Ways to a Healthy Heart, (which references the ingredient Coenzyme Q10 contained in the product Nanoemulsified CoQ10)\n\n “study on CoQ10 . . . found a 44% reduction in death from heart disease in heart failure patients supplemented with CoQ10, and a 42% reduction in death from any cause.”\n\n• Holiday Hangovers: After All That Partying, Which Nutrients Do You Need the Most (which references the ingredient Coenzyme Q10 contained in the product Nanoemulsified CoQ10)\n\no “Feed Your Mitochondria with CoEnzyme Q10 . . .—breakthrough research into these tiny energy powerhouses that stud our cells has now connected them to . . . our ability to . . . directly fight pathogens and bacteria. If there is one nutrient that is essential for mitochondria, it is CoQ10.”\n\no “Alcohol can deplete CoQ10. Supplementing with this nutrient has been found to protect the liver from oxidative stress and improve inflammation associated with fatty infiltration of the liver. It has also been shown to protect the liver from alcohol-related damage.”\n\nCat’s Claw Elite\n\nQuickSilverScientific.com\u002FBlog\n\n• 6 Tips for having a Healthy, Happy Holiday Season\n\no “Vitamin D [an ingredient in Cat’s Claw Elite] supports immunity by increasing the activity of monocytes and macrophages, immune cells that directly fight pathogens, and by increasing the production of antimicrobial peptides . . ..”\n\no “Monolaurin [an ingredient in Cat’s Claw Elite] . . . has immune modulating properties and antimicrobial effects against a variety of bacteria and viruses.”\n\nNanoemulsified Milk Thistle\n\nQuickSilverScientific.com\u002FBlog\n\n• 6 Tips for having a Healthy, Happy Holiday Season\n\no “Milk thistle [an ingredient in Nanoemulsified Milk Thistle] . . . protects liver cells from the harmful effects of alcohol . . . Supplementing with milk thistle after a particularly indulgent holiday party may ease your discomfort and help you recover faster.”\n\nLiposomal GABA with L-Theanine product web page:\n\n• “Stress and mental strain can . . . impair sleep. Return to a state of balance with . . . GABA + L-theanine . . ..”\n\nYour products Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine are not generally recognized as safe and effective for the above-referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your Nanoemulsified Milk Thistle, Cat’s Claw Elite, Nanoemulsified CoQ10 and Liposomal GABA with L Theanine products fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Hanna L. Potter, Compliance Officer; 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087 or via email at hanna.potter@fda.hhs.gov. You may reach Ms. Potter at (303) 236-3094 if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations Division West 4","Quicksilver Scientific","quicksilver-scientific-612476-10132021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquicksilver-scientific-612476-10132021","2026-10-26T08:09:46.245661+00:00","Closed Out","2021-11-09","612476","DrugsFood & Beverages","2024-10-03","Christopher W. Shade, PhD","2026-08-20T02:27:54.654+00:00","VIA UPS","2021-10-13",{"id":140,"raw":141,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":150,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":155,"body_fetched_at":156,"delivery_method":71,"recipient_title":19,"reference_number":157,"action_taken_date":158,"medical_device_id":19,"response_letter_date":19},513,[142,143,144,11,145,13,13,13],"\u003Ctime datetime=\"2025-11-04T05:00:00Z\">11\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-10T04:00:00Z\">10\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fscientific-protein-laboratories-llc-712578-10102025\">Scientific Protein Laboratories, LLC\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Denise Kwiatkowski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Regulatory Affairs Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Scientific Protein Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>700 East Main Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waunakee\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>53597\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-02\u003C\u002Fp>\u003Cp>October 10, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Kwiatkowski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Scientific Protein Laboratories, LLC, FEI 2111173, at 700 East Main Street, Waunakee, from April 21 to May 2, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 23, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific deviations, including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture multiple animal-derived APIs. During the inspection, our investigators observed numerous grooves and scratches on the API contact surface of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> table, where you perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> and initial processing of organs such as pancreases, used in the manufacture of pancrelipase. These grooves and scratches indicate that your process generates \u003Cstrong>(b)(4)\u003C\u002Fstrong> and may lead to contamination of your API with particulate matter (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> or particles).\u003C\u002Fp>\u003Cp>In your response, you state that you serviced the affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> table to remove scratches, conducted an inspection of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> tables in use to identify any additional units with similar wear or damage, and decommissioned and replaced these units. You indicated that you control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles using \u003Cstrong>(b)(4)\u003C\u002Fstrong> that can detect \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not provide a preventive maintenance plan to ensure that your resurfaced \u003Cstrong>(b)(4)\u003C\u002Fstrong> table is suitable for manufacturing. Additionally, your response lacks an evaluation of whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> table is made of a material that is adequate to minimize the introduction of foreign metal particles into your APIs. Furthermore, you did not provide details about your process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> particle removal. FDA is concerned that \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in size may pose a risk to patients. You failed to conduct a risk assessment of APIs within expiry that may have been contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all batches within expiry that could have been affected by \u003Cstrong>(b)(4)\u003C\u002Fstrong> introduced as a result of your manufacturing process, including an evaluation of retain samples for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a review of consumer complaints for the last three years.\u003C\u002Fli>\u003Cli>An evaluation of your process and equipment to determine whether changes can be implemented to remove the risk of foreign material introduced to APIs because of process design and materials.\u003C\u002Fli>\u003Cli>A validation report of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a study conducted to justify the presence of extraneous \u003Cstrong>(b)(4)\u003C\u002Fstrong> up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your APIs. Your corrective action and preventive action (CAPA) plan should focus on significantly reducing the maximum size of foreign particles generated by your manufacturing process.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to establish and follow written procedures for investigating critical deviations or the failure of intermediates and API lots to meet specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct adequate investigations into out-of-specification (OOS) results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your investigation into \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay failures during stability testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> thyroid-powder lots identified your sampling procedure as the potential root cause. You revised the procedure to require \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples from \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations within the API drum. You performed assay testing on new samples using this revised procedure and obtained passing results. Your investigation did not include sufficient evidence or rationale to support your purported root cause. FDA is concerned with your practice of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampling, which has the capability to mask individually failing testing results. Additionally, this drug is a narrow therapeutic index, where content uniformity is critical.\u003C\u002Fli>\u003Cli>You investigated lipase assay failure during stability testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> distributed pancreatin lots, but you failed to expand your investigation to other pancreatin lots. You also failed to notify your customers about these failing stability results, according to your procedure.\u003C\u002Fli>\u003Cli>Your 2023 investigation into a failure of residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit, a release specification in pancreatic enzyme concentrate, identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a potential root cause, affecting \u003Cstrong>(b)(4)\u003C\u002Fstrong> and subsequent \u003Cstrong>(b)(4)\u003C\u002Fstrong> specification failure. You implemented CAPA, but subsequently you had an additional residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> limit failure in 2024. While you did not release these batches, your investigation lacked an adequate root cause analysis to assess all sources of variability in your manufacturing process that could be contributing to the failures.\u003C\u002Fli>\u003Cli>FDA documented multiple batch rejections based on positive \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge that you rejected these batches and recognize \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a known risk factor in animal-derived APIs. The manufacturing processes for both thyroid and pancrelipase products are inherently high-risk because traditional viral clearance methods are generally not feasible, thus requiring a control strategy of discarding any \u003Cstrong>(b)(4)\u003C\u002Fstrong>-positive material. Critical gaps in the investigation of positive \u003Cstrong>(b)(4)\u003C\u002Fstrong> results in the affected pancrelipase products included inadequate evaluation of cleaning procedures between contaminated batches, failure to extend the investigation beyond positive batches to all source material, and failure to assess whether thyroid lots and infected pancreas material were sourced from the same supplier.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you revised your investigation procedure to ensure consistent and robust root-cause determination, to establish scope requirements to assess potential impact on other lots and manufacturing processes, to require CAPA determination for all critical and major investigations, and to establish explicit instructions to inform clients to place APIs on hold until the completion of the investigation.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not demonstrate that you adequately identify root cause, implement effective remediations, and expand the investigation to evaluate the effect(s) on other batches or APIs. Additionally, your response fails to provide adequate details about your CAPAs and fails to provide supporting documentation for your CAPAs.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPAs, and recurring problems that compromise the ability to manufacture safe and effective APIs.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and provide your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2111173 and ATTN: Rokhsana Safaai-Jazi.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-26-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Denise Kwiatkowski\n\nRecipient Title\n\nRegulatory Affairs Manager\n\nScientific Protein Laboratories, LLC\n\n700 East Main Street\n\nWaunakee, WI 53597\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-02\nOctober 10, 2025\nDear Ms. Kwiatkowski:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Scientific Protein Laboratories, LLC, FEI 2111173, at 700 East Main Street, Waunakee, from April 21 to May 2, 2025.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 23, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific deviations, including but not limited to the following:\n1. Failure to ensure that equipment surfaces in contact with raw materials, intermediates and API do not alter the quality of the intermediates and API beyond the official or other established specifications.\nYou manufacture multiple animal-derived APIs. During the inspection, our investigators observed numerous grooves and scratches on the API contact surface of a (b)(4) table, where you perform (b)(4) and initial processing of organs such as pancreases, used in the manufacture of pancrelipase. These grooves and scratches indicate that your process generates (b)(4) and may lead to contamination of your API with particulate matter (e.g., (b)(4) or particles).\nIn your response, you state that you serviced the affected (b)(4) table to remove scratches, conducted an inspection of all (b)(4) tables in use to identify any additional units with similar wear or damage, and decommissioned and replaced these units. You indicated that you control for (b)(4) particles using (b)(4) that can detect (b)(4) from (b)(4) to (b)(4).\nYour response is inadequate because it does not provide a preventive maintenance plan to ensure that your resurfaced (b)(4) table is suitable for manufacturing. Additionally, your response lacks an evaluation of whether the (b)(4) table is made of a material that is adequate to minimize the introduction of foreign metal particles into your APIs. Furthermore, you did not provide details about your process for (b)(4) particle removal. FDA is concerned that (b)(4) from (b)(4) to (b)(4) in size may pose a risk to patients. You failed to conduct a risk assessment of APIs within expiry that may have been contaminated with (b)(4).\nIn response to this letter, provide:\nA retrospective, independent review of all batches within expiry that could have been affected by (b)(4) introduced as a result of your manufacturing process, including an evaluation of retain samples for (b)(4) and a review of consumer complaints for the last three years.\nAn evaluation of your process and equipment to determine whether changes can be implemented to remove the risk of foreign material introduced to APIs because of process design and materials.\nA validation report of your (b)(4) and a study conducted to justify the presence of extraneous (b)(4) up to (b)(4) in your APIs. Your corrective action and preventive action (CAPA) plan should focus on significantly reducing the maximum size of foreign particles generated by your manufacturing process.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n2. Failure to establish and follow written procedures for investigating critical deviations or the failure of intermediates and API lots to meet specifications.\nYou failed to conduct adequate investigations into out-of-specification (OOS) results. For example:\nYour investigation into (b)(4) assay failures during stability testing of (b)(4) thyroid-powder lots identified your sampling procedure as the potential root cause. You revised the procedure to require (b)(4) samples from (b)(4) locations within the API drum. You performed assay testing on new samples using this revised procedure and obtained passing results. Your investigation did not include sufficient evidence or rationale to support your purported root cause. FDA is concerned with your practice of (b)(4) sampling, which has the capability to mask individually failing testing results. Additionally, this drug is a narrow therapeutic index, where content uniformity is critical.\nYou investigated lipase assay failure during stability testing of (b)(4) distributed pancreatin lots, but you failed to expand your investigation to other pancreatin lots. You also failed to notify your customers about these failing stability results, according to your procedure.\nYour 2023 investigation into a failure of residual (b)(4) limit, a release specification in pancreatic enzyme concentrate, identified (b)(4) in the (b)(4) as a potential root cause, affecting (b)(4) and subsequent (b)(4) specification failure. You implemented CAPA, but subsequently you had an additional residual (b)(4) limit failure in 2024. While you did not release these batches, your investigation lacked an adequate root cause analysis to assess all sources of variability in your manufacturing process that could be contributing to the failures.\nFDA documented multiple batch rejections based on positive (b)(4) test results for (b)(4). We acknowledge that you rejected these batches and recognize (b)(4) is a known risk factor in animal-derived APIs. The manufacturing processes for both thyroid and pancrelipase products are inherently high-risk because traditional viral clearance methods are generally not feasible, thus requiring a control strategy of discarding any (b)(4)-positive material. Critical gaps in the investigation of positive (b)(4) results in the affected pancrelipase products included inadequate evaluation of cleaning procedures between contaminated batches, failure to extend the investigation beyond positive batches to all source material, and failure to assess whether thyroid lots and infected pancreas material were sourced from the same supplier.\nIn your response, you state that you revised your investigation procedure to ensure consistent and robust root-cause determination, to establish scope requirements to assess potential impact on other lots and manufacturing processes, to require CAPA determination for all critical and major investigations, and to establish explicit instructions to inform clients to place APIs on hold until the completion of the investigation.\nYour response is inadequate because it does not demonstrate that you adequately identify root cause, implement effective remediations, and expand the investigation to evaluate the effect(s) on other batches or APIs. Additionally, your response fails to provide adequate details about your CAPAs and fails to provide supporting documentation for your CAPAs.\nInadequate investigations can lead to unidentified root causes, ineffective CAPAs, and recurring problems that compromise the ability to manufacture safe and effective APIs.\nIn response to this letter, provide a comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include but not be limited to significant improvements in investigation competencies, scope determination, root-cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are appropriately conducted.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any deviations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice, including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any deviations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and provide your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 2111173 and ATTN: Rokhsana Safaai-Jazi.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Scientific Protein Laboratories, LLC","scientific-protein-laboratories-llc-712578-10102025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fscientific-protein-laboratories-llc-712578-10102025","2026-10-26T08:09:54.506564+00:00","2025-11-04","712578","Ms. Denise Kwiatkowski","2026-08-19T16:12:09.654+00:00","320-26-02","2025-10-10",{"id":160,"raw":161,"subject":102,"body_html":165,"body_text":166,"firm_name":167,"letter_id":168,"created_at":18,"fei_number":19,"letter_url":169,"updated_at":170,"action_type":22,"case_status":23,"posted_date":171,"marcs_cms_no":172,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":173,"body_fetched_at":174,"delivery_method":175,"recipient_title":19,"reference_number":176,"action_taken_date":177,"medical_device_id":19,"response_letter_date":19},1137,[162,163,164,11,102,13,13,13],"\u003Ctime datetime=\"2024-12-10T14:20:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-13T05:00:00Z\">11\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-four-es-scientific-co-ltd-692061-11132024\">Guangzhou Four E’s Scientific Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nelson Wan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Official Correspondent \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangzhou Four E’s Scientific Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5th Floor, Building C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>No. 2 Rui Tai Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huangpu Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>510700\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-15\u003C\u002Fp>\n\n\u003Cp>November 13, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wan:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request, and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Guangzhou Four E’s Scientific Co. Ltd., FEI 3009155756, at 5th Floor, Building C, No. 2 Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700, China.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to have adequate oversight and procedures for your contract manufacturing organization (CMO) to ensure that they operate in compliance with CGMPs.\u003C\u002Fp>\n\n\u003Cp>Your firm utilized a CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to perform manufacturing, processing, and packaging activities on your behalf. You received drug products from this CMO and declared your firm as the manufacturer on import records.\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your firm did not effectively exercise its CGMP responsibilities. Specifically, your firm’s QU failed to ensure that all drug products produced for your firm possessed appropriate quality attributes. For example, your quality agreement indicates that you establish your quality requirements and your CMO must satisfy the quality requirements. Your product is labeled as sterile. However, in your response dated March 18, 2024, you submitted specifications from your CMO for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;product labeled as sterile, showing microbiological testing with specifications of “≤\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for aerobic plate count.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Sterile products introduced to the U.S. market must meet United States Pharmacopeia (USP) &lt;71&gt;, Sterility Tests, to be free from viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>Further, drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>A 704(a)(4) records review of your CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, found significant violations of CGMP including, but not limited to, inadequate testing of raw materials, incomplete process validation and inadequate testing of finished products. These CGMP violations render the products manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. FDA placed products offered for import to the United States from \u003Cstrong>(b)(4)\u003C\u002Fstrong> on Import Alert \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and issued Warning Letter \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You, including your QU, are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov&gt;media&gt;download.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations, including an evaluation of your contract manufacturer qualification program, to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003Cbr>\n&nbsp; &nbsp; o A complete evaluation of drug product specifications for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine whether the specifications are appropriate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 17, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured for Guangzhou Four E’s Scientific Co., Ltd., at No. 2 Ruitai Road, Huangpu District, Guangzhou, Guangdong, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009155756 and ATTN: Maria Pavco.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Attachment from firm email dated March 18, 2024: Annex 18.2 \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-15\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nelson Wan\n\nRecipient Title\n\nOfficial Correspondent\n\nGuangzhou Four E’s Scientific Co., Ltd.\n\n5th Floor, Building C\n\nNo. 2 Rui Tai Road\n\nHuangpu Qu\n\nGuangzhou Shi\n\nGuangdong Sheng, 510700\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-15\n\nNovember 13, 2024\n\nDear Mr. Wan:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 4, 2024 request, and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Guangzhou Four E’s Scientific Co. Ltd., FEI 3009155756, at 5th Floor, Building C, No. 2 Ruitai Road, Huangpu District, Guangzhou, Guangdong 510700, China.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\nYour firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) failed to have adequate oversight and procedures for your contract manufacturing organization (CMO) to ensure that they operate in compliance with CGMPs.\n\nYour firm utilized a CMO, (b)(4), to perform manufacturing, processing, and packaging activities on your behalf. You received drug products from this CMO and declared your firm as the manufacturer on import records.\n\nThe records and information you provided demonstrate that your firm did not effectively exercise its CGMP responsibilities. Specifically, your firm’s QU failed to ensure that all drug products produced for your firm possessed appropriate quality attributes. For example, your quality agreement indicates that you establish your quality requirements and your CMO must satisfy the quality requirements. Your product is labeled as sterile. However, in your response dated March 18, 2024, you submitted specifications from your CMO for your (b)(4) product labeled as sterile, showing microbiological testing with specifications of “≤(b)(4)” for aerobic plate count.1 Sterile products introduced to the U.S. market must meet United States Pharmacopeia (USP) \u003C71>, Sterility Tests, to be free from viable microorganisms.\n\nFurther, drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nA 704(a)(4) records review of your CMO, (b)(4), found significant violations of CGMP including, but not limited to, inadequate testing of raw materials, incomplete process validation and inadequate testing of finished products. These CGMP violations render the products manufactured by (b)(4) adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act. FDA placed products offered for import to the United States from (b)(4) on Import Alert (b)(4), on (b)(4), and issued Warning Letter (b)(4) on (b)(4).\n\nYou, including your QU, are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov>media>download.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations, including an evaluation of your contract manufacturer qualification program, to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\no A complete evaluation of drug product specifications for the (b)(4) to determine whether the specifications are appropriate.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on October 17, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured for Guangzhou Four E’s Scientific Co., Ltd., at No. 2 Ruitai Road, Huangpu District, Guangzhou, Guangdong, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009155756 and ATTN: Maria Pavco.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n____________________\n\n1 Attachment from firm email dated March 18, 2024: Annex 18.2 (b)(4)","Guangzhou Four E’s Scientific Co., Ltd.","guangzhou-four-es-scientific-co-ltd-692061-11132024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangzhou-four-es-scientific-co-ltd-692061-11132024","2026-10-26T08:08:51.336405+00:00","2024-12-10","692061","Mr. Nelson Wan","2026-08-19T17:39:45.142+00:00","VIA Electronic Mail","320-25-15","2024-11-13",{"id":179,"raw":180,"subject":184,"body_html":185,"body_text":186,"firm_name":187,"letter_id":188,"created_at":107,"fei_number":19,"letter_url":189,"updated_at":190,"action_type":22,"case_status":23,"posted_date":191,"marcs_cms_no":192,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":193,"body_fetched_at":194,"delivery_method":175,"recipient_title":19,"reference_number":19,"action_taken_date":195,"medical_device_id":19,"response_letter_date":19},2501,[181,182,183,37,184,13,13,13],"\u003Ctime datetime=\"2022-08-23T04:00:00Z\">08\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-16T04:00:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjas-diagnosticsdrew-scientific-inc-634208-08162022\">JAS Diagnostics\u002FDrew Scientific, Inc. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jean Felix LaCroix\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>JAS Diagnostics\u002FDrew Scientific, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14100 NW 57th Ct\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami Lakes\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33014-3107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Flacroix@JASdrew.com\"> Flacroix@JASdrew.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS# (634208)\u003C\u002Fp>\u003Cp>August 16, 2022\u003C\u002Fp>\u003Cp>Dear Mr. LaCroix:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 14100 NW 57th Ct, Miami Lakes, FL 33014-3107 on April 15, 2022 through April 28, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and repackager\u002Frelabeler of \u003Cem>in vitro\u003C\u002Fem> diagnostic (IVD) Chemistry, Hematology Reagents. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Mr. Felix LaCroix, CEO dated May 13, 2022 and June 10, 2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, you have not adequately implemented your complaint handling procedure titled “\u003Cem>Customer Complaint Handling”, Doc. # EQA 6.2\u003C\u002Fem>, in that complaints were not adequately documented, investigated, and evaluated for Medical Device Reportable (MDR) events.\u003Cbr>For example,\u003C\u002Fp>\u003Cp>A. Complaints received alleging deficiencies to damaged products during shipping are not documented, evaluated, and investigated according to your complaint handling procedure “\u003Cem>Customer Complaint Handling\u003C\u002Fem>”, Doc. # EQA 6.2. Your firm received 25 complaints in 2021-2022 associated with products arriving damaged, leaking, or controls out-of-temperature which were documented in a spreadsheet log titled “Customer Complaint Log”. Nineteen (19) of these complaints were associated with reagents and controls for your Drew3 analyzer, while 6 complaints were associated to the veterinary \u003Cstrong>(b)(4)\u003C\u002Fstrong> analyzer. Only one of these complaints, C21-04-01, was documented as per EQA 6.3, evaluated for MDR, and investigated. Further, your firm did not maintain records for these “non-technical” complaints for 2020.\u003C\u002Fp>\u003Cp>B. Your complaint handling procedure Doc. # EQA 6.2 states that instrument complaints will be handled according to procedure “Instrument Service and Complaints”, Doc. # IESD 1.0. Instrument complaints are entered into \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a “case”. Your firm does not maintain adequate documentation of communications received regarding the performance of the Drew3 analyzer instruments that include an evaluation to determine whether an investigation is necessary, and the evaluation of potential adverse events associated with the reported event. 119 of 277 \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases entered from January 2020 - April 2022 were associated to troubleshooting and service activities for the Drew3 Analyzer system. We reviewed 52 cases associated to the Drew3 Analyzer and found 48 did not have the MDR event evaluation, and 50 did not have the results of the investigation. Of the 4 reports with an MDR evaluation, two were not reviewed and signed off by Quality Assurance as per “Customer Complaint Handling”, Doc. # EQA 6.2.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish CAPA procedures as required by 21 CFR 820.100(a). Specifically,\u003C\u002Fp>\u003Cp>A. The investigations of failures were not extended to evaluate the adequacy of the root cause analysis process and to identify other products potentially affected by the root cause, and CAPAs were closed without identifying root cause or completing actions. For example,\u003C\u002Fp>\u003Cp>i. CAPA 21-002 was initiated on 09\u002F19\u002F2021 to investigate multiple complaints from different customers reporting boxes of products arriving broken\u002Fdamaged\u002Fwet, leaking bottles, and kits that appeared to have been hastily put together during April – July 2021. Your investigation root cause stated \u003Cstrong>(b)(4)\u003C\u002Fstrong> mishandled the packages during transit, without an adequate investigation to determine this conclusion. As a result, no corrective actions were implemented, and the Verification of Effectiveness (VOE) failed as additional complaints for damaged and leaking products were received from November 2021 - February 2022. Furthermore, your firm failed to extend the investigation to determine if the design change of the caps for the Enzymatic Cleaner and Lytic Reagent, its design change validation, and its process validation, were adequate. Six of the complaints received from 06\u002F8\u002F2021 – 07\u002F14\u002F2021 were associated to Drew3 Pac Reagent Kit, Lots #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, which were produced with the new caps for these two reagents. No further actions have been taken for this CAPA after it failed VOE and the CAPA has remained open without further actions since 11\u002F24\u002F2021.\u003C\u002Fp>\u003Cp>ii. CAPA 21-001 was initiated on 04\u002F16\u002F2021 to investigate complaints related to high background counts on various lots of FS-Pak Test Kits for your veterinary hematology device \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your root cause for CAPA 21-001 indicated that the laboratory analysis identified presence of particles in the diluent of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> composition which your firm attributed to the set parameters of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer which produced excessive heat and melting of the polymer layer of the FS- Pak Test Kits caps. However, these settings had been validated and in use since \u003Cstrong>(b)(4)\u003C\u002Fstrong> under validation protocol # VP-015-005 and had passed your tests. Validation protocol #VP-015- 005 also validated this \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer for the Drew3-Pac 5L Diluent Reagent. Our review of the validation #VP-015-005 identified inadequate process validation to test the seal integrity. This CAPA 21-001 failed to extend the investigation to the Drew3-Pac 5L Diluent to determine if the \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealing parameters for the Drew3-Pac 5L Diluent bottles also affected this product and may have also contributed to the particles that were found in the diluent that were attributed to the Recall # Z-1576-2016 for high background counts as your previous CAPA 16-006 did not characterize the material of the particles found in those bottles. This CAPA remains open.\u003C\u002Fp>\u003Cp>iii. CAPA 19-010 was initiated on \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to two complaints received for Alanine Aminotransferase (ALT), Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, reporting ABSLim error. The CAPA found the ABSLim error appeared to be related to the decrease of the reagent absorbance but could not identify the reason for the absorbance not reaching specifications at 12 months expiration. Your firm closed this CAPA 19-010 within two months without a root cause on 07\u002F26\u002F2019 with a recommendation to monitor the performance of the reagent by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A new CAPA 19-012 was opened two months later on 09\u002F13\u002F2019 due to the failed VOE of CAPA 19-010 to continue to investigate the ABSLim error and decrease of absorbance of the Alanine Aminotransferase (ALT). However, this CAPA 19-012 was also closed on 11\u002F30\u002F2020 without completion of an investigation. Further, no adequate evaluation or actions were conducted to address the impacted lots of products in commercial distribution.\u003C\u002Fp>\u003Cp>iv. CAPA 19-011 was initiated on \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to corrective actions that failed Verification of Effectiveness to address an internal audit nonconformance ANR#16-005. This CAPA was closed on 11\u002F19\u002F2021 citing those corrective actions had not been completed as the employees responsible for Facilities &amp; Maintenance and implementation of the CAPA were no longer with the company. It also stated that a new Action Item will be added to your firm’s Quality Plan, Doc. # QP-2020-01, Rev. 2, to review the structure of your departments and ensure all managers have trained employees to act as back-up to continue to conduct activities when an employee is absent. We found continued deficiencies in Facilities &amp; Maintenance in that the current Equipment Inspection Log for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system continues to demonstrate lack of good documentation practices and the records for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring showed \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not sampled and tested from 02\u002F25\u002F2019 through 09\u002F21\u002F2021 and from 02\u002F10\u002F2022 through 04\u002F04\u002F2022 due to absence of personnel.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>CAPA deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>B. You are not adequately trending quality indicators such as complaints, services, nonconformances, laboratory out-of-specification results, and manufacturing rejection rates, using appropriate statistical methodology where necessary to detect recurring quality problems. For example, your current trending report only trends the number of services and preventive maintenance performed and does not include cases of troubleshooting. Your review also fails to trend by product, issue, device identification number, or other factors as needed to detect recurring problems. No other quality data trending is performed.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also states your intention to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and describes that you gathered data for complaints, services, non-conformances, out-of-specification lab results, manufacturing deviations, troubleshooting, and preventive maintenance for review and trend analysis. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish a process whose results cannot be fully verified by subsequent inspection and test according to established procedures as required by 21 CFR 820.75(a). Specifically, you have not adequately implemented your process validation procedure, “\u003Cem>Validation Procedure”, Doc # EMF 1.0\u003C\u002Fem>. For example,\u003C\u002Fp>\u003Cp>A. Your firm has no documented evidence of the process validation for the mixing, filling, and capping of the Drew3-Pac Diluent and Enzymatic Cleaner reagents and the mixing validation for the Lysing reagent currently manufactured at your facility which compose the Drew3-Pac kit for use with your Drew3 Analyzer. Further, your firm has not completed the process validations for the JAS Chemistry IVDs including \u003Cstrong>(b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>B. Your firm did not adequately conduct the process validation for the new \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer used for the Drew3-Pac Diluent 5L bottle caps, Validation # VP-021-007. The following deficiencies were noted:\u003C\u002Fp>\u003Cp>i. The Operational Qualification (OP) “Heat Seal Integrity Test” consisted of only visual inspection of the seal and visual inspection for leaks of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles filled with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no justification for the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and for the sample size to be representative of a production lot of Drew3-Pac Diluent which consists of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles.\u003Cbr>ii. The Product Performance Qualification (PPQ) states it was conducted with only one production lot of Drew3-Pac Diluent, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Device History Record (DHR) for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not indicate that the diluent bottles were sealed with your new magnetic induction sealer being validated, instead, the DHR for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates the bottle caps were sealed using your previous \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat sealer, ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>iii. The conveyor belt speed parameter was set to 4.8-5, but your OQ states it was set and run at 5.2.\u003C\u002Fp>\u003Cp>C. Your firm did not adequately conduct the process validation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat induction sealer, ID #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Validation # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used for the D3 Diluent 5L bottles until Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, last filled on 09\u002F24\u002F2021. The “heat seal integrity test” consisted of only visual inspection of the seal and visual inspection for leaks of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles. There was no justification for the sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles to be representative of a production lot of Drew3-Pac Diluent which consists of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles. Your visual inspection of the heat seal integrity test indicated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles passed at sealer parameters of 100% power and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, a documented deviation indicated that Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and the following two production lots were found to have a small number of caps\u002Fseals leaking which was not evident initially. As a result, your firm adjusted the sealer time from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> but repeated the same visual test again on only \u003Cstrong>(b)(4)\u003C\u002Fstrong> additional bottles.\u003C\u002Fp>\u003Cp>D. Your firm has not conducted validation of the off-the-shelf \u003Cstrong>(b)(4)\u003C\u002Fstrong> software used to manage warehouse activities (in-coming, inventory, status, distribution), BOM preparation, and service orders to verify the software meets your needs and intended uses.\u003C\u002Fp>\u003Cp>E. You have not validated the microbial test method performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Process validation deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your validation procedure and includes a Retrospective Validation Report for your DREW3-PAC. It also indicates that you are planning to create a validation protocol for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> software and are gathering documentation and data to amend the validation summary reports for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> induction sealer and \u003Cstrong>(b)(4)\u003C\u002Fstrong> heat induction sealer. You also promised to perform an in-house verification for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> test method. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>4. Failure to establish design control procedures as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your design control procedure “\u003Cem>Design Controls”, Doc. # ER&amp;D 4.1\u003C\u002Fem> in that your firm has not adequately completed implementation of corrections to observations cited during previous inspections associated to Design History File (DHF), design reviews, risk assessment, and shipping validation. For example,\u003C\u002Fp>\u003Cp>A. Your firm has not adequately maintained a Design History File (DHF) for the Drew3 Analyzer system that includes design inputs, design outputs, design reviews, design verification, design validation, and design changes for the system which includes the analyzer, controls, calibrators, and reagents. Your firm conducted a retroactive review of a DHF as correction to previous observations. However, the file presented to us was a DHF exclusively for the Drew3-Pac kit reagents (Diluent, Enzymatic Cleaner, Lysing reagents). Furthermore, we found the retrospective review was inadequate in that the DHF did not include the design input and design output specifications for product packaging including the reagent bottles, caps, and packaging components as well as no documentation of the design change evaluation to the bottle caps of the Diluent, Lysing reagent, and Enzymatic Cleaner and their new specifications.\u003C\u002Fp>\u003Cp>B. The design change validation for the new caps of the 5L Diluent, Doc. #VP-020-001, and validation for the new caps for the Lysing Reagent and Enzymatic Cleaner bottles, Doc. #VP- 021-001, were inadequate:\u003C\u002Fp>\u003Cp>i. Doc. #VP-021-001: The validation did not evaluate the impact to the capper, magnetic induction sealer, and torque requirements for the new caps which had different specifications from the previous caps, there is no rationale for the sampling size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles from a lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate. Your firm received five complaints for product damaged and\u002For leaking on D3-Pac Reagent kits Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and one complaint for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> between 06\u002F08\u002F2021 and 07\u002F14\u002F2021 after implementation of the new caps.\u003C\u002Fp>\u003Cp>ii. Doc. #VP-020-001: The validation did not evaluate the impact to the capper, heat induction sealer, and torque requirements, there is no rationale for the sampling size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from a lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate.\u003C\u002Fp>\u003Cp>C. Your firm has not conducted shipping validation for the EX-TROL controls and EX-CAL calibrators that require \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C storage. Your firm documented at least five complaints for “hot” or “damaged” controls received between March 2021 – September 2021.\u003C\u002Fp>\u003Cp>D. Your firm has not evaluated the instructions on the Operator’s Manual for the dilution of the sodium hypochlorite. For example, according to the current \u003Cem>Operator’s Manual, M- Drew3-US- OP, Rev. 1.07, September 2019\u003C\u002Fem>, the user is to perform this cleaning per scheduled maintenance recommendation (monthly or more frequent if processing more than 50 samples per day) or as necessary when there is excessive rejection (*, R-CL, W-CL) for one measured parameter using a Sodium Hypochlorite solution (bleach) at 12% in chloride. However, your firm identified that the bleach solution you use must be a particular grocery chain brand with 7.5% sodium hypochlorite further diluted to approximately 3% in chloride. We also identified complaints that required the use of 50% bleach solution and running the bleach cycle up to 3 times as part of the troubleshooting. Your firm has not validated the use of the Sodium Hypochlorite solution concentration and the frequency of use stated in the Operator’s Manual.\u003C\u002Fp>\u003Cp>E. Your firm failed to adequately implement risk management procedure “\u003Cem>Risk Management Process”, Doc. # EQA 4.2\u003C\u002Fem>. Your complaint handling procedure Doc. # EQA 6.2 states that risk assessment must be performed in accordance with EQA 4.2 for each complaint to determine possible impact to safety, new hazards\u002Fhazardous situations, and\u002For increased risks from existing hazards. However, none of the complaints reviewed found this risk assessment is being performed for each complaint. Furthermore, we identified hazards noted in complaints that were not listed in your risk analysis files. For example, the risk analysis for the Drew3 analyzer, “\u003Cem>Risk Analysis Project”, D3, Version 9, dated 12\u002F22\u002F2014\u003C\u002Fem>, does not include the following hazardous situations:\u003C\u002Fp>\u003Cp>i. Needle mis-positioning and possible needle plunging twice into the same chamber\u003Cbr>ii. Sample needle leaking during sampling\u003Cbr>iii. Counting chamber broken with reported problem with hemoglobin (HGB) count\u003Cbr>iv. Pressure default errors\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Design Control deficiencies were previously communicated to your firm in our 2009 FDA 483, 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It also states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish procedures for the control of product that does not conform to specified requirements as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your non-conforming product procedures. For example,\u003C\u002Fp>\u003Cp>A. Your firm did not adequately implement “\u003Cem>Nonconforming Material Control and Material Review Board Procedures”, Doc. # EQA 5.0\u003C\u002Fem>. On 04\u002F05\u002F2022, we observed two pallets of 5L bottles, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used for the Drew3-Pac Diluent in your filling room labeled as “Do Not Use”. Your firm indicated that the bottles of these two pallets had been found to have defects including holes on the handles which caused leakage of the Diluent during the filling process. One pallet was received on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and another on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not document this non-conformance as per EQA 5.0, failed to document an evaluation of the affected product lots filled with this lot of bottles, and failed to document the disposition of those filled bottles. The Device History Records (DHR) also had no record of this non-conformance.\u003C\u002Fp>\u003Cp>B. Your firm is not adequately implementing the laboratory procedure “Out of Specification (OOS) Investigations”, Doc. # \u003Cem>EQC 2.0\u003C\u002Fem>, for documenting and investigating Out of Specification results obtained during quality testing of your products. For example,\u003C\u002Fp>\u003Cp>EX-TROL Control Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Low, Normal, and High) exhibited results out-of-range on various instruments during June 2021. Examples include the following:\u003C\u002Fp>\u003Cp>i. 06\u002F21\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. 06\u002F23\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. 06\u002F28\u002F2021: \u003Cstrong>(b)(4)\u003C\u002Fstrong> in instrument serial numbers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your laboratory was unable to provide information if any samples were processed on the above- mentioned days, possible reason for these failures observed for Control \u003Cstrong>(b)(4)\u003C\u002Fstrong> in three separate instruments on the same days, or any actions taken.\u003C\u002Fp>\u003Cp>C. You are not adequately implementing your procedure “\u003Cem>DREW3 Lysing Reagent Bulk Testing and Disposition”, Doc. # EQC 4.0\u003C\u002Fem>. The low control \u003Cstrong>(b)(4)\u003C\u002Fstrong> exhibited inadequate readings during the quality control run performed prior to the Drew3-Pac Lysing Reagent Bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample on 06\u002F09\u002F2021 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this control \u003Cstrong>(b)(4)\u003C\u002Fstrong> was re-run and obtained a passing result which was included in the manufacturing record, but the out-of- specification result was not documented in the DHR.\u003C\u002Fp>\u003Cp>D. You are not adequately implementing your procedure \u003Cem>EQC 3.3 “Test and Disposition for DREW-3 PAC Reagents Kits\u003C\u002Fem>” which states that sections 6.8.2 the Background (3 Diluents) and 6.8.3 Kit Recovery (Controls Low, Normal, and High, and 3 samples) do not meet acceptance criteria, the kit shall \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and recorded in a new FEQC 3.31 form. We observed this procedure not being adequately implemented in that there is no documentation for the following missing results or sequences of samples missing in between samples. For example,\u003C\u002Fp>\u003Cp>Finished Drew3-Pac kits, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\u003Cp>i. Kit #1 is missing the results for Diluent #3, Control \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Control \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and sequence \u003Cstrong>(b)(4)\u003C\u002Fstrong> between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. Kit #2 is missing sequences 8240-8244 between Diluent 1 and Diluent 2 and sequences 8251-8252 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. Kit #3 is missing sequences 10859-10860 between Diluent 1 and Diluent 2 and sequences \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Sample 1 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iv. Kit #4 is missing the results of Diluent 2, Diluent 3, Controls L, N, H and sequence 27855 between Sample 2 and Sample 3 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>v. Kit #5 is missing sequences 42381-42384 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Finished Drew3-Pac, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\u003Cp>i. Kit #1 is missing sequence 7602, 7604 and 7607 between Controls in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the Controls shows Control L (low) and Control N (normal) were out-of-range.\u003C\u002Fp>\u003Cp>ii. Kit #2 is missing sequence 8621 between Diluent 1 and Diluent 2, sequence 8627 between Control Low and Sample 1 and sequence 8629 in between samples in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>iii. Kit #3 is missing sequence 7020 between Control L and Sample 1, and sequence 7022 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the controls shows Control L (low) was out-of-range.\u003C\u002Fp>\u003Cp>iv. Kit #5 is missing sequence 28220 between Control N and Control H, and sequence 28222 between Control H and Sample 1, and sequence 28224 between Sample 1 and Sample 2 in instrument S\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Quality Control Report for the controls shows Control L (low) and Control (normal) were out-of-range.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response to the 483 regarding Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> states that you issued a SCAR to the supplier and are investigating\u002Fgathering all documentation regarding Lot “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. You also promised to investigate and document OOS results correctly and revise or amend all missing sequences or data listed in Observation 5D for the affected lots. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish procedures for acceptance as required by 21 CFR 820.80(a). Specifically, your firm is not adequately implementing incoming quality control procedure “\u003Cem>Procedure for the Inspection, QC Verification, and Release of Hematology Controls”, Doc # EQC 16.0\u003C\u002Fem>, to test and release new lots of Hematology Controls received at your facility. EQC 16.0 requires running each type of control (low, normal, high) three times using two hematology analyzers, however, your firm ran each type of control only once in two analyzers for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to conduct a deviation investigation for Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong> and provide justification. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>7. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements. Specifically,\u003C\u002Fp>\u003Cp>A. You have not adequately implemented your supplier control procedure “\u003Cem>Supplier\u002FService Provider Qualification Program\u003C\u002Fem>”, \u003Cem>Doc. # EQA 7.0\u003C\u002Fem>. For example,\u003C\u002Fp>\u003Cp>i. Your approved supplier list does not include the list of all your approved suppliers, contractors, and consultant(s) as per your procedure.\u003C\u002Fp>\u003Cp>ii. You have not documented the evaluation of your quality consultant and your supplier that supplies your bleach used to service Drew3 Analyzers and as raw material for your Hema- Clenz.\u003C\u002Fp>\u003Cp>iii. Your evaluation of your contract manufacturers is inadequate in that you have not ensured that your contract manufacturers have adequately validated their manufacturing process such as the injection molding process of the 5L diluent bottles.\u003C\u002Fp>\u003Cp>iv. You did not ensure that appropriate corrective actions were taken by your supplier. For example, your firm issued a request via e-mail for investigation and corrective action to your supplier of your 5L bottles after bottles were found to have holes. This action was not documented as a Supplier Corrective Action Request (SCAR) as per your procedure. The contract manufacturer provided their Corrective Action Report, date completed 02\u002F04\u002F2021, with an inadequate investigation and indicated possible root cause due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Their corrective action states that they would \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not ensure that the contract manufacturer of the bottles verified or validated this corrective action and adequately implemented this action. Your firm received another pallet of defective bottles of the same lot on 04\u002F01\u002F2021 after implementation of this correction.\u003C\u002Fp>\u003Cp>B. Your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0, does not define when an on-site audit is necessary.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Purchasing Control deficiencies were previously communicated to your firm in our 2019 FDA 483 and 2020 Untitled Letter.\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your supplier qualification procedure and reevaluate all suppliers to ensure they remain qualified. You also promised to revise your master vendor list. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Additionally, the following has also been noted about your firm and corrective actions should be addressed in your response:\u003C\u002Fp>\u003Cp>8. On your webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd3) for the D3 hematology analyzer, in the “Performance” segment, under “Part Code” section, the following information about the instrumentation and its description are incorrect and should be removed.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Part Code\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Description\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>BAR-9000-221\u003C\u002Ftd>\u003Ctd>2280 Hematology analyzer with computer &amp; barcode reader\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>BAR-9001-221\u003C\u002Ftd>\u003Ctd>2280 Hematology analyzer without computer &amp; barcode reader\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>9. On the webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5) describing the D5 analyzer, it says, “FDA Clearance in Process” and “For Export Only”. The phrase “FDA Clearance in Process” should be removed.\u003C\u002Fp>\u003Cp>10. On the D5 analyzer webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5), the D3 analyzer informational video is embedded. This should be removed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # (634208) when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Wendy Blame 334-273-4789 Ext 101 or at wendy.blame@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Blake Bevill, M.S.\u003Cbr>Program Division Director\u003Cbr>Office of Medical Device and Radiological Health Operations\u003Cbr>Division 2 Central\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Jean Felix LaCroix\n\nRecipient Title\n\nOwner\u002FCEO\n\nJAS Diagnostics\u002FDrew Scientific, Inc.\n\n14100 NW 57th Ct\n\nMiami Lakes, FL 33014-3107\n\nUnited States\n\nFlacroix@JASdrew.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS# (634208)\nAugust 16, 2022\nDear Mr. LaCroix:\nDuring an inspection of your firm located at 14100 NW 57th Ct, Miami Lakes, FL 33014-3107 on April 15, 2022 through April 28, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and repackager\u002Frelabeler of in vitro diagnostic (IVD) Chemistry, Hematology Reagents. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Mr. Felix LaCroix, CEO dated May 13, 2022 and June 10, 2022 concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to the following:\n1. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a). Specifically, you have not adequately implemented your complaint handling procedure titled “Customer Complaint Handling”, Doc. # EQA 6.2, in that complaints were not adequately documented, investigated, and evaluated for Medical Device Reportable (MDR) events.\nFor example,\nA. Complaints received alleging deficiencies to damaged products during shipping are not documented, evaluated, and investigated according to your complaint handling procedure “Customer Complaint Handling”, Doc. # EQA 6.2. Your firm received 25 complaints in 2021-2022 associated with products arriving damaged, leaking, or controls out-of-temperature which were documented in a spreadsheet log titled “Customer Complaint Log”. Nineteen (19) of these complaints were associated with reagents and controls for your Drew3 analyzer, while 6 complaints were associated to the veterinary (b)(4) analyzer. Only one of these complaints, C21-04-01, was documented as per EQA 6.3, evaluated for MDR, and investigated. Further, your firm did not maintain records for these “non-technical” complaints for 2020.\nB. Your complaint handling procedure Doc. # EQA 6.2 states that instrument complaints will be handled according to procedure “Instrument Service and Complaints”, Doc. # IESD 1.0. Instrument complaints are entered into (b)(4) as a “case”. Your firm does not maintain adequate documentation of communications received regarding the performance of the Drew3 analyzer instruments that include an evaluation to determine whether an investigation is necessary, and the evaluation of potential adverse events associated with the reported event. 119 of 277 (b)(4) cases entered from January 2020 - April 2022 were associated to troubleshooting and service activities for the Drew3 Analyzer system. We reviewed 52 cases associated to the Drew3 Analyzer and found 48 did not have the MDR event evaluation, and 50 did not have the results of the investigation. Of the 4 reports with an MDR evaluation, two were not reviewed and signed off by Quality Assurance as per “Customer Complaint Handling”, Doc. # EQA 6.2.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to (b)(4). You also stated that (b)(4). The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n2. Failure to adequately establish CAPA procedures as required by 21 CFR 820.100(a). Specifically,\nA. The investigations of failures were not extended to evaluate the adequacy of the root cause analysis process and to identify other products potentially affected by the root cause, and CAPAs were closed without identifying root cause or completing actions. For example,\ni. CAPA 21-002 was initiated on 09\u002F19\u002F2021 to investigate multiple complaints from different customers reporting boxes of products arriving broken\u002Fdamaged\u002Fwet, leaking bottles, and kits that appeared to have been hastily put together during April – July 2021. Your investigation root cause stated (b)(4) mishandled the packages during transit, without an adequate investigation to determine this conclusion. As a result, no corrective actions were implemented, and the Verification of Effectiveness (VOE) failed as additional complaints for damaged and leaking products were received from November 2021 - February 2022. Furthermore, your firm failed to extend the investigation to determine if the design change of the caps for the Enzymatic Cleaner and Lytic Reagent, its design change validation, and its process validation, were adequate. Six of the complaints received from 06\u002F8\u002F2021 – 07\u002F14\u002F2021 were associated to Drew3 Pac Reagent Kit, Lots #(b)(4) and #(b)(4), which were produced with the new caps for these two reagents. No further actions have been taken for this CAPA after it failed VOE and the CAPA has remained open without further actions since 11\u002F24\u002F2021.\nii. CAPA 21-001 was initiated on 04\u002F16\u002F2021 to investigate complaints related to high background counts on various lots of FS-Pak Test Kits for your veterinary hematology device (b)(4). Your root cause for CAPA 21-001 indicated that the laboratory analysis identified presence of particles in the diluent of (b)(4), (b)(4), and (b)(4) composition which your firm attributed to the set parameters of the (b)(4) induction sealer which produced excessive heat and melting of the polymer layer of the FS- Pak Test Kits caps. However, these settings had been validated and in use since (b)(4) under validation protocol # VP-015-005 and had passed your tests. Validation protocol #VP-015- 005 also validated this (b)(4) induction sealer for the Drew3-Pac 5L Diluent Reagent. Our review of the validation #VP-015-005 identified inadequate process validation to test the seal integrity. This CAPA 21-001 failed to extend the investigation to the Drew3-Pac 5L Diluent to determine if the (b)(4) induction sealing parameters for the Drew3-Pac 5L Diluent bottles also affected this product and may have also contributed to the particles that were found in the diluent that were attributed to the Recall # Z-1576-2016 for high background counts as your previous CAPA 16-006 did not characterize the material of the particles found in those bottles. This CAPA remains open.\niii. CAPA 19-010 was initiated on (b)(4) due to two complaints received for Alanine Aminotransferase (ALT), Lot #(b)(4), reporting ABSLim error. The CAPA found the ABSLim error appeared to be related to the decrease of the reagent absorbance but could not identify the reason for the absorbance not reaching specifications at 12 months expiration. Your firm closed this CAPA 19-010 within two months without a root cause on 07\u002F26\u002F2019 with a recommendation to monitor the performance of the reagent by (b)(4). A new CAPA 19-012 was opened two months later on 09\u002F13\u002F2019 due to the failed VOE of CAPA 19-010 to continue to investigate the ABSLim error and decrease of absorbance of the Alanine Aminotransferase (ALT). However, this CAPA 19-012 was also closed on 11\u002F30\u002F2020 without completion of an investigation. Further, no adequate evaluation or actions were conducted to address the impacted lots of products in commercial distribution.\niv. CAPA 19-011 was initiated on (b)(4) due to corrective actions that failed Verification of Effectiveness to address an internal audit nonconformance ANR#16-005. This CAPA was closed on 11\u002F19\u002F2021 citing those corrective actions had not been completed as the employees responsible for Facilities & Maintenance and implementation of the CAPA were no longer with the company. It also stated that a new Action Item will be added to your firm’s Quality Plan, Doc. # QP-2020-01, Rev. 2, to review the structure of your departments and ensure all managers have trained employees to act as back-up to continue to conduct activities when an employee is absent. We found continued deficiencies in Facilities & Maintenance in that the current Equipment Inspection Log for the (b)(4) system continues to demonstrate lack of good documentation practices and the records for the (b)(4) system monitoring showed (b)(4) was not sampled and tested from 02\u002F25\u002F2019 through 09\u002F21\u002F2021 and from 02\u002F10\u002F2022 through 04\u002F04\u002F2022 due to absence of personnel.\nCAPA deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nB. You are not adequately trending quality indicators such as complaints, services, nonconformances, laboratory out-of-specification results, and manufacturing rejection rates, using appropriate statistical methodology where necessary to detect recurring quality problems. For example, your current trending report only trends the number of services and preventive maintenance performed and does not include cases of troubleshooting. Your review also fails to trend by product, issue, device identification number, or other factors as needed to detect recurring problems. No other quality data trending is performed.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response indicates that you plan to (b)(4). It also states your intention to (b)(4) and describes that you gathered data for complaints, services, non-conformances, out-of-specification lab results, manufacturing deviations, troubleshooting, and preventive maintenance for review and trend analysis. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n3. Failure to adequately establish a process whose results cannot be fully verified by subsequent inspection and test according to established procedures as required by 21 CFR 820.75(a). Specifically, you have not adequately implemented your process validation procedure, “Validation Procedure”, Doc # EMF 1.0. For example,\nA. Your firm has no documented evidence of the process validation for the mixing, filling, and capping of the Drew3-Pac Diluent and Enzymatic Cleaner reagents and the mixing validation for the Lysing reagent currently manufactured at your facility which compose the Drew3-Pac kit for use with your Drew3 Analyzer. Further, your firm has not completed the process validations for the JAS Chemistry IVDs including (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), (b)(4), and (b)(4).\nB. Your firm did not adequately conduct the process validation for the new (b)(4) induction sealer used for the Drew3-Pac Diluent 5L bottle caps, Validation # VP-021-007. The following deficiencies were noted:\ni. The Operational Qualification (OP) “Heat Seal Integrity Test” consisted of only visual inspection of the seal and visual inspection for leaks of (b)(4) bottles filled with (b)(4). There was no justification for the use of (b)(4) and for the sample size to be representative of a production lot of Drew3-Pac Diluent which consists of (b)(4) bottles.\nii. The Product Performance Qualification (PPQ) states it was conducted with only one production lot of Drew3-Pac Diluent, Lot (b)(4). The Device History Record (DHR) for Lot (b)(4) does not indicate that the diluent bottles were sealed with your new magnetic induction sealer being validated, instead, the DHR for Lot (b)(4) indicates the bottle caps were sealed using your previous (b)(4) heat sealer, ID #(b)(4).\niii. The conveyor belt speed parameter was set to 4.8-5, but your OQ states it was set and run at 5.2.\nC. Your firm did not adequately conduct the process validation for the (b)(4) heat induction sealer, ID #(b)(4), Validation # (b)(4), used for the D3 Diluent 5L bottles until Lot #(b)(4), last filled on 09\u002F24\u002F2021. The “heat seal integrity test” consisted of only visual inspection of the seal and visual inspection for leaks of (b)(4) bottles. There was no justification for the sample size of (b)(4) bottles to be representative of a production lot of Drew3-Pac Diluent which consists of (b)(4) bottles. Your visual inspection of the heat seal integrity test indicated that the (b)(4) bottles passed at sealer parameters of 100% power and (b)(4). However, a documented deviation indicated that Lot #(b)(4) and the following two production lots were found to have a small number of caps\u002Fseals leaking which was not evident initially. As a result, your firm adjusted the sealer time from (b)(4) to (b)(4) but repeated the same visual test again on only (b)(4) additional bottles.\nD. Your firm has not conducted validation of the off-the-shelf (b)(4) software used to manage warehouse activities (in-coming, inventory, status, distribution), BOM preparation, and service orders to verify the software meets your needs and intended uses.\nE. You have not validated the microbial test method performed on the (b)(4) system using the (b)(4).\nProcess validation deficiencies were previously communicated to your firm in our 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your validation procedure and includes a Retrospective Validation Report for your DREW3-PAC. It also indicates that you are planning to create a validation protocol for your (b)(4) software and are gathering documentation and data to amend the validation summary reports for your (b)(4) induction sealer and (b)(4) heat induction sealer. You also promised to perform an in-house verification for the (b)(4) test method. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n4. Failure to establish design control procedures as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your design control procedure “Design Controls”, Doc. # ER&D 4.1 in that your firm has not adequately completed implementation of corrections to observations cited during previous inspections associated to Design History File (DHF), design reviews, risk assessment, and shipping validation. For example,\nA. Your firm has not adequately maintained a Design History File (DHF) for the Drew3 Analyzer system that includes design inputs, design outputs, design reviews, design verification, design validation, and design changes for the system which includes the analyzer, controls, calibrators, and reagents. Your firm conducted a retroactive review of a DHF as correction to previous observations. However, the file presented to us was a DHF exclusively for the Drew3-Pac kit reagents (Diluent, Enzymatic Cleaner, Lysing reagents). Furthermore, we found the retrospective review was inadequate in that the DHF did not include the design input and design output specifications for product packaging including the reagent bottles, caps, and packaging components as well as no documentation of the design change evaluation to the bottle caps of the Diluent, Lysing reagent, and Enzymatic Cleaner and their new specifications.\nB. The design change validation for the new caps of the 5L Diluent, Doc. #VP-020-001, and validation for the new caps for the Lysing Reagent and Enzymatic Cleaner bottles, Doc. #VP- 021-001, were inadequate:\ni. Doc. #VP-021-001: The validation did not evaluate the impact to the capper, magnetic induction sealer, and torque requirements for the new caps which had different specifications from the previous caps, there is no rationale for the sampling size of (b)(4) bottles from a lot of (b)(4) bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate. Your firm received five complaints for product damaged and\u002For leaking on D3-Pac Reagent kits Lot #(b)(4) and one complaint for Lot #(b)(4) between 06\u002F08\u002F2021 and 07\u002F14\u002F2021 after implementation of the new caps.\nii. Doc. #VP-020-001: The validation did not evaluate the impact to the capper, heat induction sealer, and torque requirements, there is no rationale for the sampling size of (b)(4) from a lot of (b)(4) bottles, and the leak test consisting of visual examination and no defined pressure applied is inadequate.\nC. Your firm has not conducted shipping validation for the EX-TROL controls and EX-CAL calibrators that require (b)(4)°C storage. Your firm documented at least five complaints for “hot” or “damaged” controls received between March 2021 – September 2021.\nD. Your firm has not evaluated the instructions on the Operator’s Manual for the dilution of the sodium hypochlorite. For example, according to the current Operator’s Manual, M- Drew3-US- OP, Rev. 1.07, September 2019, the user is to perform this cleaning per scheduled maintenance recommendation (monthly or more frequent if processing more than 50 samples per day) or as necessary when there is excessive rejection (*, R-CL, W-CL) for one measured parameter using a Sodium Hypochlorite solution (bleach) at 12% in chloride. However, your firm identified that the bleach solution you use must be a particular grocery chain brand with 7.5% sodium hypochlorite further diluted to approximately 3% in chloride. We also identified complaints that required the use of 50% bleach solution and running the bleach cycle up to 3 times as part of the troubleshooting. Your firm has not validated the use of the Sodium Hypochlorite solution concentration and the frequency of use stated in the Operator’s Manual.\nE. Your firm failed to adequately implement risk management procedure “Risk Management Process”, Doc. # EQA 4.2. Your complaint handling procedure Doc. # EQA 6.2 states that risk assessment must be performed in accordance with EQA 4.2 for each complaint to determine possible impact to safety, new hazards\u002Fhazardous situations, and\u002For increased risks from existing hazards. However, none of the complaints reviewed found this risk assessment is being performed for each complaint. Furthermore, we identified hazards noted in complaints that were not listed in your risk analysis files. For example, the risk analysis for the Drew3 analyzer, “Risk Analysis Project”, D3, Version 9, dated 12\u002F22\u002F2014, does not include the following hazardous situations:\ni. Needle mis-positioning and possible needle plunging twice into the same chamber\nii. Sample needle leaking during sampling\niii. Counting chamber broken with reported problem with hemoglobin (HGB) count\niv. Pressure default errors\nDesign Control deficiencies were previously communicated to your firm in our 2009 FDA 483, 2014 FDA 483, 2019 FDA 483, and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to (b)(4). It also states that you plan to (b)(4). The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n5. Failure to adequately establish procedures for the control of product that does not conform to specified requirements as required by 21 CFR 820.30(a). Specifically, you have not adequately implemented your non-conforming product procedures. For example,\nA. Your firm did not adequately implement “Nonconforming Material Control and Material Review Board Procedures”, Doc. # EQA 5.0. On 04\u002F05\u002F2022, we observed two pallets of 5L bottles, Lot (b)(4), used for the Drew3-Pac Diluent in your filling room labeled as “Do Not Use”. Your firm indicated that the bottles of these two pallets had been found to have defects including holes on the handles which caused leakage of the Diluent during the filling process. One pallet was received on (b)(4) and another on (b)(4). Your firm did not document this non-conformance as per EQA 5.0, failed to document an evaluation of the affected product lots filled with this lot of bottles, and failed to document the disposition of those filled bottles. The Device History Records (DHR) also had no record of this non-conformance.\nB. Your firm is not adequately implementing the laboratory procedure “Out of Specification (OOS) Investigations”, Doc. # EQC 2.0, for documenting and investigating Out of Specification results obtained during quality testing of your products. For example,\nEX-TROL Control Lot # (b)(4) (Low, Normal, and High) exhibited results out-of-range on various instruments during June 2021. Examples include the following:\ni. 06\u002F21\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4) in (b)(4)\nii. 06\u002F23\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4)\niii. 06\u002F28\u002F2021: (b)(4) in instrument serial numbers (b)(4), (b)(4) and (b)(4)\nYour laboratory was unable to provide information if any samples were processed on the above- mentioned days, possible reason for these failures observed for Control (b)(4) in three separate instruments on the same days, or any actions taken.\nC. You are not adequately implementing your procedure “DREW3 Lysing Reagent Bulk Testing and Disposition”, Doc. # EQC 4.0. The low control (b)(4) exhibited inadequate readings during the quality control run performed prior to the Drew3-Pac Lysing Reagent Bulk (b)(4) sample on 06\u002F09\u002F2021 in instrument S\u002FN (b)(4). However, this control (b)(4) was re-run and obtained a passing result which was included in the manufacturing record, but the out-of- specification result was not documented in the DHR.\nD. You are not adequately implementing your procedure EQC 3.3 “Test and Disposition for DREW-3 PAC Reagents Kits” which states that sections 6.8.2 the Background (3 Diluents) and 6.8.3 Kit Recovery (Controls Low, Normal, and High, and 3 samples) do not meet acceptance criteria, the kit shall (b)(4) ((b)(4)) and recorded in a new FEQC 3.31 form. We observed this procedure not being adequately implemented in that there is no documentation for the following missing results or sequences of samples missing in between samples. For example,\nFinished Drew3-Pac kits, Lot (b)(4):\ni. Kit #1 is missing the results for Diluent #3, Control (b)(4), Control (b)(4), and sequence (b)(4) between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\nii. Kit #2 is missing sequences 8240-8244 between Diluent 1 and Diluent 2 and sequences 8251-8252 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\niii. Kit #3 is missing sequences 10859-10860 between Diluent 1 and Diluent 2 and sequences (b)(4) and (b)(4) for Sample 1 in instrument S\u002FN (b)(4)\niv. Kit #4 is missing the results of Diluent 2, Diluent 3, Controls L, N, H and sequence 27855 between Sample 2 and Sample 3 in instrument S\u002FN (b)(4)\nv. Kit #5 is missing sequences 42381-42384 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4)\nFinished Drew3-Pac, Lot (b)(4):\ni. Kit #1 is missing sequence 7602, 7604 and 7607 between Controls in instrument S\u002FN (b)(4). The Quality Control Report for the Controls shows Control L (low) and Control N (normal) were out-of-range.\nii. Kit #2 is missing sequence 8621 between Diluent 1 and Diluent 2, sequence 8627 between Control Low and Sample 1 and sequence 8629 in between samples in instrument S\u002FN (b)(4)\niii. Kit #3 is missing sequence 7020 between Control L and Sample 1, and sequence 7022 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4). The Quality Control Report for the controls shows Control L (low) was out-of-range.\niv. Kit #5 is missing sequence 28220 between Control N and Control H, and sequence 28222 between Control H and Sample 1, and sequence 28224 between Sample 1 and Sample 2 in instrument S\u002FN (b)(4). The Quality Control Report for the controls shows Control L (low) and Control (normal) were out-of-range.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response to the 483 regarding Lot (b)(4) states that you issued a SCAR to the supplier and are investigating\u002Fgathering all documentation regarding Lot “(b)(4)”. You also promised to investigate and document OOS results correctly and revise or amend all missing sequences or data listed in Observation 5D for the affected lots. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n6. Failure to adequately establish procedures for acceptance as required by 21 CFR 820.80(a). Specifically, your firm is not adequately implementing incoming quality control procedure “Procedure for the Inspection, QC Verification, and Release of Hematology Controls”, Doc # EQC 16.0, to test and release new lots of Hematology Controls received at your facility. EQC 16.0 requires running each type of control (low, normal, high) three times using two hematology analyzers, however, your firm ran each type of control only once in two analyzers for Lot #(b)(4).\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to conduct a deviation investigation for Lot #(b)(4) and provide justification. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\n7. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements. Specifically,\nA. You have not adequately implemented your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0. For example,\ni. Your approved supplier list does not include the list of all your approved suppliers, contractors, and consultant(s) as per your procedure.\nii. You have not documented the evaluation of your quality consultant and your supplier that supplies your bleach used to service Drew3 Analyzers and as raw material for your Hema- Clenz.\niii. Your evaluation of your contract manufacturers is inadequate in that you have not ensured that your contract manufacturers have adequately validated their manufacturing process such as the injection molding process of the 5L diluent bottles.\niv. You did not ensure that appropriate corrective actions were taken by your supplier. For example, your firm issued a request via e-mail for investigation and corrective action to your supplier of your 5L bottles after bottles were found to have holes. This action was not documented as a Supplier Corrective Action Request (SCAR) as per your procedure. The contract manufacturer provided their Corrective Action Report, date completed 02\u002F04\u002F2021, with an inadequate investigation and indicated possible root cause due to the (b)(4). Their corrective action states that they would (b)(4). However, your firm did not ensure that the contract manufacturer of the bottles verified or validated this corrective action and adequately implemented this action. Your firm received another pallet of defective bottles of the same lot on 04\u002F01\u002F2021 after implementation of this correction.\nB. Your supplier control procedure “Supplier\u002FService Provider Qualification Program”, Doc. # EQA 7.0, does not define when an on-site audit is necessary.\nPurchasing Control deficiencies were previously communicated to your firm in our 2019 FDA 483 and 2020 Untitled Letter.\nWe reviewed your firm’s response but are unable to assess the adequacy of your response as the corrections are in progress. Your response states your intent to review and revise your supplier qualification procedure and reevaluate all suppliers to ensure they remain qualified. You also promised to revise your master vendor list. The adequacy of your response cannot be determined at this time. A follow-up inspection by FDA is necessary to verify compliance.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nAdditionally, the following has also been noted about your firm and corrective actions should be addressed in your response:\n8. On your webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd3) for the D3 hematology analyzer, in the “Performance” segment, under “Part Code” section, the following information about the instrumentation and its description are incorrect and should be removed.\nPart CodeDescription\nBAR-9000-2212280 Hematology analyzer with computer & barcode reader\nBAR-9001-2212280 Hematology analyzer without computer & barcode reader\n\n9. On the webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5) describing the D5 analyzer, it says, “FDA Clearance in Process” and “For Export Only”. The phrase “FDA Clearance in Process” should be removed.\n10. On the D5 analyzer webpage (https:\u002F\u002Fwww.drewscientific.com\u002Fd5), the D3 analyzer informational video is embedded. This should be removed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # (634208) when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Wendy Blame 334-273-4789 Ext 101 or at wendy.blame@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBlake Bevill, M.S.\nProgram Division Director\nOffice of Medical Device and Radiological Health Operations\nDivision 2 Central","JAS Diagnostics\u002FDrew Scientific, Inc.","jas-diagnosticsdrew-scientific-inc-634208-08162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjas-diagnosticsdrew-scientific-inc-634208-08162022","2026-10-26T08:09:02.919481+00:00","2022-08-23","634208","Mr. Jean Felix LaCroix","2026-08-20T01:38:34.418+00:00","2022-08-16",9,{"510k":198,"classification":199,"enforcement":200,"event":201,"event_backfill":202,"pma":203,"warning_letter":204},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]